Version Date: 11 -30-2021  UPCC 21520  
1 
 UPCC 21520 
 
The LIMIT KRAS  Mutant NSCLC Trial: Lysosome Inhibition to Enhance M APK Inhibition 
Targeting KRAS Mutant NSCLC : A Phase 2  Open Label Trial of Binimetinib and 
Hydroxychloroquine in Patients with Advanced KRAS  Mutant Non-Small Cell Lung 
Cancer  
 
University of Pennsylvania Department of Medicine, Division of Hematology -Oncology   
 
 
Principal Investigator:   Charu Aggarwal MD, MPH  
    Perelman Center for Advanced Medicine  
    10th Floor, South Tower Extension 
3400 Civic Center Blvd  
215-662-6318 
Charu.Aggarwal @pennmedicine.upenn.edu 
 
Sub-Investigators:             Ravi Amaravadi, MD  
Corey J. Langer, MD  
Roger B. Cohen, MD  
Aditi Singh, MD  
Melina Marmarelis, MD  
Lova Sun, MD  
Christine Ciunci, MD  
Christopher D’Avella, MD  
Ryan Massa, MD  
Victoria Sherry, DNP  
Susan Stonehouse-Lee, CRNP  
Elizabeth Gilbert, PA -C 
Faith Mutale, CRNP  
Beth Sandy, CRNP  
Gloria DiLullo, CRNP  
Christina Knepley, CRNP  
Lindsay Dougherty, DNP  
 Tomas Aleman, MD  
Christine Ciunci MD  
Christopher D’Avella MD  
Ryan Massa MD  
Meghan O’N eill, CRNP  
 
Biostatistician:   Rosemarie Mick, MS  
 
 
Medical Monitor :  Kim Reiss -Binder  
 
Funding:  Pfizer  
Drug s Supplied: Binimetinib 
 
Hydroxychloroquine:  Commercially available  
 
Version Date: 11 -30-2021  UPCC 21520  
2 
 IND status:  IND exempt  
 
Initial version:   11-10-2020 
PI Change:  06-29-2021 
Amendment :   11-30-2021 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Version Date: 11 -30-2021  UPCC 21520  
3 
 STUDY SUMMARY  .............................................................................................................................................. 5 
1.0 OBJECTIVES  ........................................................................................................................................... 7 
1.1 PRIMARY OBJECTIVES  ......................................................................................................................................... 7 
1.2 SECONDARY OBJECTIVES  ..................................................................................................................................... 7 
1.3 CORRELATIVE OBJECTIVES  ................................................................................................................................... 7 
2.0 BACKGROUND AND RATIO NALE  ............................................................................................................. 8 
2.1 PATIENT POPULATION  ........................................................................................................................................ 8 
2.2 RATIONAL E FOR COMBINED LYSOSOMAL AND AUTOPHAGY INHIBITION  ........................................................................ 8 
2.3 BINIMETINIB  .................................................................................................................................................... 9 
2.3.1  Binimetinib: Clinical Safety  ...................................................................................................................... 9 
2.4 HYDROXYCHLOROQUINE (HCQ)  ........................................................................................................................... 9 
2.4.1  Clinical Experience of HCQ in cancer trials  ............................................................................................... 9 
2.5 RATIONALE FOR CORRELATIVE STUDIES  ................................................................................................................ 10 
3.0 PATIENT SELECTION  .............................................................................................................................. 10 
3.1 INCLUSION CRITERIA  ........................................................................................................................................ 10 
3.2 EXCLUSION CRITERIA  ........................................................................................................................................ 11 
4.0 TREATMENT PLAN  ................................................................................................................................ 12 
4.1 OVERVIEW  ..................................................................................................................................................... 12 
4.2 HYDROXYCHLOROQUINE ADMINISTRATION  ........................................................................................................... 12 
4.3 BINIMETINIB ADMINISTR ATION  ........................................................................................................................... 13 
4.4 CONCOMITANT MEDICATION AND PROCEDURES  ................................................................................................... 13 
4.5 DURATION OF PROTOCOL TREATMENT AND FOLLOW -UP ........................................................................................ 13 
5.0 TOXICITY CRITERIA, M ONITORING, DOSE DELA YS AND MODIFICATIONS  ................................................ 13 
5.1 TOXICITY CRITERIA  ........................................................................................................................................... 13 
5.2 DOSE DELAYS ................................................................................................................................................. 13 
5.3 TOXICITIES AND DOSE MODIFICATIONS  ................................................................................................................ 14 
5.3.1  Ocular Toxicity  ....................................................................................................................................... 17 
5.3.2  Hydrox ychloroquine Dose Reduction  ..................................................................................................... 20 
6.0 PHARMACEUTICAL INFORMATION ........................................................................................................ 20 
6.1 HYDROXYCHLOROQUINE  ................................................................................................................................... 20 
6.2 BINIME TINIB  .................................................................................................................................................. 21 
7.0 CORRELATIVE STUDIES  .......................................................................................................................... 22 
7.1 OVERVIEW OF CORRELATIVE STUDIES . ................................................................................................................. 22 
7.2 HCQ  PHARMACOKINETICS  ................................................................................................................................ 22 
7.2.1  Clinical Pharmacology of HCQ and rationale for population PK Studies  ................................................ 22 
7.2.2  Pharmacokinetic Sample Collections  ..................................................................................................... 23 
7.2.3  Bioanalytic Methods and PK analysis.  ................................................................................................... 23 
7.3 PHARMACODYNAMIC STUDIES IN TUMOR TISS UES .................................................................................................. 24 
7.3.1  Serial Tumor Biopsies and analysis.  ....................................................................................................... 24 
7.3.2  Measuring autophagy induction and autophagy inhibition in tumor tissue.  ........................................ 25 
7.3.3  Therapy -induced gene expression changes in the tissue microenvironment.  ........................................ 25 
7.4 BLOOD BASED CORRELATI VE STUDIES  ................................................................................................................... 25 
7.4.1  Plasma biomarkers for autophagy dynamics  ......................................................................................... 25 
7.4.2  Methods for Collecting Plasma  .............................................................................................................. 26 
7.4.3  FFPE archival tumor tissue for genetic analysis.  .................................................................................... 27 
8.0 STUDY CALENDAR  ................................................................................................................................ 28 
9.0 MEASUREMENT OF EFFECT  ................................................................................................................... 31 
9.1 DEFINITIONS  .................................................................................................................................................. 31 
9.2 DISEASE PARAMETERS  ......................................................................................................................................  31 
9.3 METHODS FOR EVALUATION OF MEASURABLE DISEASE  .......................................................................................... 32 
9.4 RESPONSE CRITERIA  ......................................................................................................................................... 32 
9.4.1  Evaluation of Target Lesions  .................................................................................................................. 32 
9.4.2  Evaluation of Non- Target Lesions  .......................................................................................................... 33 
Version Date: 11 -30-2021  UPCC 21520  
4 
 9.4.3  Evaluation of Best Overall Response  ...................................................................................................... 33 
9.4.4  Duration of Resp onse  ............................................................................................................................. 34 
9.4.5  Progression -Free Survival  ....................................................................................................................... 34 
9.4.6  Overall Survival ......................................................................................................................................  34 
9.4.7  Off treatment/Off Study  ........................................................................................................................ 34 
10.0 ADVERSE EVENTS AND REPORTING  ....................................................................................................... 34 
10.1 ADVERSE  EVENTS  ............................................................................................................................................ 35 
10.2 RECORDING OF ADVERSE EVENTS . ...................................................................................................................... 35 
10.2.1  Serious Adverse Events  ...................................................................................................................... 36 
10.3 ASSESSMENT OF ADVERSE EVENTS  ...................................................................................................................... 36 
10.3.1  Relationship to study drug: Yes  ......................................................................................................... 37 
10.3.2  Relationship to study drug: No  .......................................................................................................... 37 
10.3.3  Diagnosis vs. Signs and Symptoms  .................................................................................................... 38 
10.3.4  Deaths  ............................................................................................................................................... 38 
10.3.5  Preexisting Medical Conditions  ......................................................................................................... 38 
10.3.6  Pregnancy  .......................................................................................................................................... 38 
10.4 SAE  REPORTING TO ARRAY  ............................................................................................................................... 38 
10.5 UPENN  IRB NOTIFICATION BY INVESTIGATOR -SPONSOR  ........................................................................................ 39 
10.5.1  Reporting Process to IRB at Penn.  ..................................................................................................... 41 
10.5.2  FDA Notification by Investigator -Sponsor.  ........................................................................................ 41 
10.6 MEDICAL MONITORING  .................................................................................................................................... 41 
10.7 STUDY MONITORING PLAN ............................................................................................................................... 41 
10.8 AUDITING AND INSPECTING  ............................................................................................................................... 41 
11.0 STATISTICAL CONSIDERATIONS  ............................................................................................................. 42 
11.1 DESIGN  ......................................................................................................................................................... 42 
11.2 OBJECTIVES  .................................................................................................................................................... 42 
11.3 ENDPOINTS  .................................................................................................................................................... 42 
11.4 SIMON 2-STAGE DESIGN  ................................................................................................................................... 43 
11.5 PLANS FOR DATA ANALYSIS  ............................................................................................................................... 43 
11.6 SAMPLE SIZE .................................................................................................................................................. 44 
11.7 STUDY DURATION  ........................................................................................................................................... 44 
REFERENCES  ...................................................................................................................................................... 45 
APPENDIX A: ECOG PER FORMANCE STATUS ...................................................................................................... 47 
APPENDIX B:  DEFINIT ION OF NON- CHILDBEAR ING POTENTIAL AND ME DICALLY ACCEPTABLE M ETHODS OF 
BIRTH CONTROL  ................................................................................................................................................ 48 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
Version Date: 11 -30-2021  UPCC 21520  
5 
 STUDY SUMMARY  
 
Title The LIMIT KRAS  Mutant NSCLC Trial: Lysosome Inhibition to 
Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A 
Phase 2 Open Label Trial of Binimetinib and 
Hydroxychloroquine in Patients with Advanced KRAS  Mutant 
Non-Small Cell Lung Cancer  
 
Protocol Number  UPCC 21520  
Phase Phase 2  
Methodology  Single Arm  
Study Duration 2 years  
Study Center(s)  Single Center  
Objectives Primary Objectives  
 
• Determine the Objective Response Rate (ORR) of 
binimetinib (B) and hydroxychloroquine(HCQ), as measured 
by RECIST 1.1 
• Determine the safety/tolerability of B+  HCQ, as measured by 
CTCAE 5.0 
 
Secondary Objectives  
• Progression -Free Survival  
• Overall Survival  
• Measurement of changes in circulating tumor DNA (ctDNA) 
KRAS allelic frequency  
• Measurement of changes in biomarkers related to 
autophagy  
 
Number of Subjects Stage 1: 10 patients  
Stage 2: 19 patients  
Total:  Up to 29 patients  
Diagnosis and Main 
Inclusion/Exclusion 
Criteria  • Must be ≥ 18 years of age.  
•  Metastatic or incurable NSCLC  
• Presence of a non-synonymous mutation in KRAS 
• Must have received at least one prior systemic therapy 
for metastatic NSCLC, or be intolerant/otherwise 
ineligible for such therapy  
• Must have ECOG performance status of 0 or 1  
•  Must have adequate renal, liver, cardiac and 
hematological function  
• Must be able to provide written informed consent. 
• Must have at least one measurable lesion according to 
Response Evaluation Criteria for Solid Tumors (RECIST 
1.1) 
• Patients with asymptomatic or treated, stable brain 
metastases are allowed to enroll.  Patients with 
carcinomatous meningitis are excluded.   
Version Date: 11 -30-2021  UPCC 21520  
6 
  
Study Product, Dose, 
Route, Regimen Hydroxychloroquine 400 mg by mouth every 12 hours  (obtained 
commercially) , binimetinib 45 mg 2 times daily  
Duration of administr ation Until progression, unacceptable toxicity , or withdrawal of 
consent.    
Study design  Phase  2: Optimal Simon  2-stage design with the first stage 
recruiting 10 patients, and 19 additional patients if there are > 2 
responses seen .  
Duration of trial • Approximately 2 years  
• Follow -up:  
o All subjects will be evaluated per study calendar for 6 months after discontinuation of study treatment 
o All subjects will be followed for a minimum of 
one year from the start of treatment, unless 
disease progression is reported prior to one 
year.  
 
 
 
Version Date: 11 -30-2021  UPCC 21520  
7 
 1.0 OBJECTIVES  
1.1 Primary Objectives  
• To assess  the clinical efficacy of HCQ  + B by ORR.  
• Determine the safety/tolerability of HCQ  + B as measured by CTCAE 5 .0. 
1.2 Secondary Objectives 
• To measure the progression-free survival  among patients treated with HCQ+B  
• To measure the overall survival among patients treated with HCQ+B . 
1.3 Correlative Objectives 
• To evaluate the correlation between response to HCQ  + B and pre-treatment tumor 
staining for PPT1, LC3, ALDH1A1, and HLTF by immunohistochemistry.  
• To monitor changes on a repeat biopsy  after 3 weeks of treatment with HCQ  + B in 
PPT1, LC3, ALDH1A1, and HLTF by immunohistochemistry , as well as in gene 
signatur es. 
• To measure the change in median number of autophagic vesicles/cell (mAV/cell) in 
serially collected tumor tissue with HCQ  + B. 
• To determine if blood based candidate biomarkers of autophagy modulation ( including 
IL-8, Interleukin-1 Beta, LIF, DKK3, and FAM3C, and other serum cytokines) reflect 
autophagy dynamics in tumors of patients treated with HCQ  + B. 
• To characterize HCQ pharmacokinetics when HCQ is combined with binimetinib  
• To monitor changes in allelic fraction of KRAS in circulating tumor DNA (c tDNA) among 
patients treated with HCQ + B  
 
  
Version Date: 11 -30-2021  UPCC 21520  
8 
 2.0 BACKGROUND AND RATIONALE  
2.1 Patient population 
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death for both men and 
women in the United States .  The use of targeted therapy based on molecular profile has 
completely changed the treatment approach for patients with genetic alterations in the EGFR, 
ALK, and ROS1 genes.  Such patients are now  routinely treated with tyrosine kinase 
inhibitors(TKIs), and the overall survival seen in these patient populations is substantially longer 
than the general population of patients with NSCLC.  Despite being the most commonly mutated 
gene in non- squamous NSCLC, KRAS has been historically very difficult to target.  The relative 
resistance of KRAS mutant NSCLC to TKI based therapy is likely related to the very strong 
affinity of KRAS for its natural ligand.  While there have been some emerging advances for 
KRAS G12C  mutant NSCLC  using allosteric inhibitors, there have been nearly no advances in 
the targeted therapy of patients with other KRAS mutations.   
2.2 Rationale for combined Lysosomal and Autophagy inhibition 
The lysosome has been found to be critical for the growth of pancreatic cancer (Perera Nature PMC5086585
). Kimmelman’s group has published multiple papers demonstrating that 
autophagy is critical for pancreatic cancer growth and targeting with chloroquine derivatives produces cytotoxicity in m ost pancreatic cancer cell lines and patient derived xenografts (Yang 
Cancer Discovery  2014; 
PMC4125497 ). The University of Pittsburgh group has done extensive 
preclinical and clinical w ork on combining HCQ with chemotherapy. A phase I/II trial of 35 
patients examined the neoadjuvant treatment with HCQ and gemcitabine in patients with 
borderline resectable pancreatic adenocarcinomas (Boone Annals of Surgery 2015; 
PMC4663459 ). 1200 mg/day of HCQ was taken for 31 days up until the day of surgery 
combined with two doses of a fixed-dose 1500 mg/m2 gemcitabine. DLT or grade 4/5 events did 
not occur during this trial. 19/35 patients had a decrease in surrogate biomarker response (CA 19-9) and 29/35 patients underwent surgical resection as scheduled. This trial demonstrated 
that HCQ with gemcitabine is  safe and tolerable, and showed encouraging activity in the 
neoadjuvant setting.  A randomized phase II trial with gemcitabine, abraxane, with or without 
HCQ in resectable pancreatic cancer patients has been launched ([STUDY_ID_REMOVED]), and a 
randomized phase II study of gemcitabine, abraxane, with or without HCQ in the metastatic 
setting ([STUDY_ID_REMOVED])  found that HCQ added to chemotherapy significantly improved 
response rate (Karasic JAMA Oncology 2019; 
PMC6547080 ). The safety and activity of 
combining dabrafenib ( BRAF inhibitor) trametinib ( MEK inhibitor) and HCQ has been 
preliminarily demonstrated in an ongoing Phase I/II trial in BRAF mutant melanoma patients 
(See below).  
 
Recently publis hed data supporting MEK  inhibitor  + HCQ combination for Ras  mutant cancer. 
Three separate teams of inv estigators  at the University of Utah, University of North Carolina 
Chapel Hill /NYU, and NCI/UCSF have found stunning activity of combining HCQ with either  
MEK (University of Utah) or ERK inhibition (UNC) in preclinical models of KRAS -driven 
pancreas cancer. The Utah group included melanoma colon and lung cancer xenografts with RAS mutations. In all cases the combination of a MEK inhibitor with HCQ was synthetic ally 
lethal to RAS  mutant cancers, with tumors regressing in each case ( Kinsey Nature Medicine 
2019 PMID:30833748; Bryant Nature Medicine 2019 PMID:30833752; Lee PNAS 2019 
PMC6410784).  This data provides the rationale for studying a MEK inhibitor in combination with 
HCQ in KRAS  mutant non-small cell lung cancer.  
 
 
Version Date: 11 -30-2021  UPCC 21520  
9 
 2.3 Binimetinib 
Binimetinib (also known as MEK162, ARRY -438162 or ONO -7703) is an orally bioavailable, 
selective and potent mitogen-activated protein (MAP) kinase kinase (MEK)1 and MEK2 inhibitor.  
Binimetinib, given in combination with encorafenib, has received marketing approval in several 
jurisdictions for the treatment of patients with BRAF -mutant melanoma as per local prescribing 
information.   
2.3.1 Binimetinib: Clinical Safety  
Binimetinib has been administered as a single agent to 943 patients with cancer across multiple 
studies.  The most frequently reported adverse events with single agent binimetinib treatment 
have been blood creatine kinase elevation, diarrhea, acneiform dermatitis, peripheral edema, rash, nausea and fatigue.  The majority of these adverse events have been grade 1 -2, with the 
exception of blood creatine kinase levations, which was seen in 21% at a grade 3-4 level in 
patients with melanoma and 29% of patients with low grade serous carcinoma of the ovary, 
fallopian tube, or primary peritoneum.    
2.4 Hydroxyc hloroquine (HCQ)  
Chloroquine (CQ) is a synthetic 4-aminoquinoline that has been used for 80 years in humans for 
malaria prophylaxis and treatment, rheumatoid arthritis , and human immunodeficiency virus 
(HIV). It is an inexpensive orally available drug that has CNS penetration. It has a large 
therapeutic index, and its most predictable cumulative toxicity is retinopathy (Marmor et al., 
2011).  It is this toxicity and worldwide malarial resistance to CQ that lead to discontinuation of 
extensive research into CQ’s non-malarial applications .  Chloroquine derivatives such as HCQ 
are still used extensively in rheumatoid arthritis and lupus erythematosis and have a larger 
therapeutic index.  The chemical s tructure of CQ derivatives allows them to serve as a weak 
base which is trapped in acidic cellular compartments  (Poole and Ohkuma, 1981). Thus 
chloroquine derivatives  deacidify  lysosomes, inhibiting the last step in autophagy. With this last 
step blocked, a cell reliant on autophagy will increase the generation of autophagosomes and will eventually undergo either apoptotic or non-apoptotic cell death. Evidence in mouse models 
and human cancer cell lines suggest CQ may have significant anti -tumor activity by inhibiting 
autophagy induced by cancer therapy  (Ama ravadi Cancer Discovery  2019 PMID:31434711)  
2.4.1 Clinical Experience of HCQ in cancer trials 
We have previously published the first 6 clinical trials involving combinations of HCQ and cancer drugs (Vogl Autophagy 2014 PMC4203515: Rosenfeld Autophagy 2014 PMC4203513
; 
Rangwala Autophagy 2014 PMC4203514; Rangwala Autophagy 2014 PMC4203516 ; 
Mahalingam Autophagy 2014 PMC4203517; Barnard Autophagy 2014 PMC4203518 ). This 
effort has demonstrated the safety of the approach in patients with advanced solid tumors. Our 
preliminary data in 2 phase I studies (presented at the Society of Melanoma Research 2016)  
demonstrates the safety and striking activity of combined BRAF and autophagy inhibition in 
BRAF  mutant melanoma. We launched a Phase I trial of vemurafenib and HCQ in BRAFV600E 
melanoma patients ([STUDY_ID_REMOVED]).  7 patients in the 1st dose level (vemurafeni b 960 po bid + 
HCQ 400 po bid) had 2 dose limiting toxicities (DLT; grade 3 rash and grade 3 transaminitis 
evaluable for response had PR or CR (median max target shrinkage -62% [ -38- -100%]). 
Prolonged PFS was seen in 1 CR (36+ mo) and 1 PR (20 mo).  Combi ned BRAF/MEK inhibition 
was adopted widely so this trial was closed, the BAMM trial, a Novartis funded multi -institution 
phase I/II trial of dabrafenib (D), trametinib (T) and HCQ was opened ([STUDY_ID_REMOVED]). Phase I 
was completed with no DLT (n=7). Recommended phase II dose was HCQ 400 bid with D+T. 
Phase II enrollment continues.   D+T+HCQ was well tolerated, with no evidence of significant 
ocular toxicity on extensive serial ophthalmological exams (Nti Retina 2018; PMC6039280 ).  
Version Date: 11 -30-2021  UPCC 21520  
10 
 Striking responses were observed: 90 % patients have responded and 48% of patients have had 
an investigator -assessed complete response.  Median PFS is roughly 18 months.  The only 
non-responder was found to have BRAFV600E amplification, and had pyrexia that required 
frequent dose interruptions.  
2.5 Rationale for correlative studies  
To test the hypothesis that HCQ could enhance the therapeutic efficacy of B by inhibiting 
autophagy, this clinical trial will incorporate sev eral correlative studies .  First, we will include 
biopsies before and after starting treatment with HCQ  + B. This will allow pathological  analysis 
including electron microscopy by which we can assess the degree of autophagy . This is feasible 
since the inhibition of the last step of autophagy by HCQ should cause an accumulation of 
autophagic vesicles that can be detected by electron microscopy and immunoblotting. Next , 
through serial  blood draws, we can investigate non-invasi ve markers by which autophagic 
dynamics may be detected. We have selected certain candidate biomarkers such as IL-8, 
Interleukin-1 Beta, LIF, DKK3, and FAM3C, based on in vitro data that shows elevated serum  
levels in human patients during high autophagy s tates  (Kraya  Autophagy  2015  PMC4502670).   
Finally, we aim to investigate the immune consequences of  autophagy inhibition by measuring 
serum cytokine levels using luminex technology.  
For all patients enrolled, we plan to obtain 20 unstained slides from archival FFPE blocks of 
ideally the latest metastatic lesion that was biopsied will be obtained. IHC assays for correlative 
autophagy biomarkers:  We have identified a 2 gene signature inv olving Aldehyde 
dehydrogenase and helicase like transcription factor (HLTF). We have developed IHC protocols for these genes. We hypothesize the patterns of expression of these genes previously identified 
in HCQ -S and HCQ -R cancer cell lines (Piao Autophagy 2017) will correlate with PFS. In 
addition, the following proteins will be measured by IHC: Phospho ERK, cleaved caspase 3,  
PPT1. Additional biomarkers and Immune cell staining will be conducted as the concept is 
developed further.  
 
 
3.0 PATIENT SELECTION  
3.1 Inclusion Criteria  
Each subject must meet all of the following inclusion criteria to be enrolled in the study:  
1) Metastatic or incurable NSCLC  
2) Presence of a non-synonymous mutation in KRAS  
3) Patient must have received at least one prior systemic therapy for m etastatic NSCLC or 
be intolerant/ineligible/refuse available therapies with known benefit  
4) Ability and willingness to sign a written informed consent document 
5) Age ≥18 years old  
6) At least one measureable lesion according to Response Evaluation Criteria in Solid 
Tumors (RECIST) 1.1 
7) ECOG performance status 0-1  
 
 
  
Version Date: 11 -30-2021  UPCC 21520  
11 
 8) Adequate organ function, as defined below  
System  Laboratory Value  
Hematological   
Absolute neutrophil count 
(ANC)  ≥1,250/mcL  
Platelets  ≥100,000/mcL  
Hemoglobin  ≥9 g/dL or ≥5.6 mmol/L  
Renal   
Serum creatinine OR 
Measured or calculateda 
creatinine clearance  
(GFR can also be used in place 
of creatinine or CrCl)  ≤1.5 X upper limit of normal (ULN) OR 
 
≥50 mL/min for subject with creatinine levels > 
1.5 X institutional ULN  
Hepatic   
Serum total bilirubin  ≤ 1.5 X ULN OR 
 Direct bilirubin ≤ ULN for subjects with total 
bilirubin levels > 1.5 ULN  
AST (SGOT) and ALT (SGPT)  ≤ 2.5 X ULN  OR 
≤ 5 X ULN for subjects with liver metastases  
aCreatinine clearance should be calculated per institutional standard.  
9) Women of childbearing potential must have a negative serum pregnancy test performed within 72hours of the first dose of study therapy.  Subjects of reproductive potential must 
agree to use acceptable birth control methods (see Appendix B for childbearing 
potential).  
10) Qtc < 500 mSec on EKG  
11) Must be able to swallow tablets  
12) Must be willing to comply with protocol procedures (including completion of diaries and outcome measures  
 
3.2 Exclusion Criteria  
A subject will not be eligible for inclusion in this study if the following criteria apply: 
 
1) Currently participating in or has participated in a study of an investigational agent or 
anticipated use of an investigational device within 4 weeks of the first dose of study treatment. 
2) Untreated symptomatic central nervous system (CNS) metastases and/or carcinomatous 
meningitis.  
3) Prior monoclonal antibody within 4 weeks prior to enrollment, or individuals who have 
not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered mor e than 4 weeks earlier.  
4) Known additional malignancy that is progressing or requires active treatment.  
Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the 
skin, non-invasive bladder tumors, or in situ cervical cancer  
5) Active  infection requiring systemic therapy with IV antibiotics  
Version Date: 11 -30-2021  UPCC 21520  
12 
 6) History or current evidence of any condition, therapy, or laboratory abnormality that 
might confound the results of the trial, interfere with the subject’s participation for the full 
duration of the trial, or is not in the best interest of the subject to participate, in the 
opinion of the treating investigator.   
7) Known psychiatric or substance abuse disorders as documented in the chart that, in the 
opinion of the investigator, would interfere with cooperation with the requirements of the 
trial. 
8) Pregnant or breastfeeding women  
9) Anticipated receipt of any live vaccine within 30 days prior to the first dose of trial 
treatment.   
10) Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO).  
11) Patients receiving cytochrome P450 enzyme-inducing anticonvulsant drugs (EIADs) (i.e. 
phenytoin, carbamazepine, Phenobarbital, primidone or oxcarbazepine) within 4 weeks 
of the start of the study treatment  
12) Known Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (subjects with 
laboratory evidence of cleared HBV and/or HCV will be permitted) 
13) Patients with a previously documented retinal vein occlusion . 
14) History or evidence of increased cardiovascular risk including any of the following:  
• Current clinically significant uncontrolled arrhythmias. 
Exception:   Subjects with controlled atrial fibrillation for > 30 days prior to 
randomization are eligible. 
• Histor y of acute coronary syndromes (including myocardial infarction and 
unstable angina), coronary angioplasty, or stenting within 6 months prior to 
randomization. 
• Ejection fraction of ≤50% as measured by echocardiography or MUGA  
15) Any other conditions judged by the investigator that would limit the evaluation of the subject.  
 
4.0 TREATMENT  PLAN  
4.1 Overview  
Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on 
day 1.  The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future 
amendment prior to the first patient enrolled.  Efforts will be made to ensure dose homogeneity 
throughout the trial.  Treatment will be administered on an outpatient bas is on a 28  day c ycle.  
Reported adverse events and potential risks for HCQ and B are described in Section 6.  
Appropriate dose modifications for HCQ and B are described in Section s 5 and 6.  No 
investigational or commercial agents or therapies other than t hose described below may be 
administered with the intent to treat the patient's malignancy. 
4.2 Hydroxychloroquine administration 
Hydroxychloroquine is an oral medication, requiring the patients on study to keep a study diary. 
Diary must be submitted at each c linic visit.  
Version Date: 11 -30-2021  UPCC 21520  
13 
  
Hydroxychloroquine should be obtained commercially.  The starting dose for HCQ will be 400. 
Tablets  of HCQ are available in 200 mg strength. HCQ will be administered in divided doses 
(every 12 hours)  with or without food.  To enhance compliance and assist in 
pharmacokinetic analysis, t he two daily doses of HCQ  should be taken 12 hours apart, 
for example, 9  AM and 9 PM, and documented clearly on the patient calendar.  Modification of 
the schedule in case of GI symptoms is allowed. Missed doses do not need to be replaced. On 
days of clinic visits, patients will be asked the date / time / dose of last HCQ taken.  This 
information will be documented on the CRF.  Patients will be asked to take HCQ continuously, 
as prescribed.  
4.3 Binimet inib administration 
The starting dose for B is 45 mg BID.  B will be administered in divided dose (every 12 hours) 
on either an empty or full stomach.  The two daily doses of B should be taken 12 hours apart, 
for example, 9 AM and 9 PM.  
4.4 Concomitant Medication and Procedures   
Because HCQ has known effects on P450 enzymes, patients requiring anti -convulsants may be 
treated with any of the non-enzyme inducing anti -convulsants which include: felbamate, valproic 
acid, gabapentin, lamotrigine, tiagibine, topiramate, or levetiracetam. Zonisamide is not recommended as this drug accumulates in red blood cells where HCQ also accumulates. For 
nausea aprepitant should be avoided. Radiation therapy to the surgical bed with gamma knife 
radiotherapy while on treatment is all owed for surgically resected brain metastases. Gamma 
knife for new CNS lesions may be performed while on study, but further of treatment of these patients will be considered treatment beyond progression ( see Section 4.5).  Binimetinib does 
not need to be taken fasting.  All other concomitant medications are permitted, but P -gp and 
BCRP inhibitors are to be administered with caution.   
4.5 Duration of Pro tocol Treatment and Follow -up 
Treatment will continue until disease progression and may continue at the discr etion of the 
treating physician in consultation with the Principal Investigator, if there is an isolated 
progression.  Treatment may also be discontinued for adverse events that delay treatment 
greater than 28 days and as outlined in Toxicities and Dose Modifications.  Please refer to Off 
Treatment/Off Study for additional reasons for study withdrawal.  S ubjects will be evaluated for 
at least 6 months after discontinuation of study treatment and will be followed for a minimum of 
one year from the start of treatment, unless disease progression is reported prior to one year.  
One year survival information will be extracted from the medical record or by phone call for 
subjects who have discontinued protocol treatment and completed the 6 month follow -up 
evaluati ons prior to one year from the start of treatment. 
 
 
5.0 TOXICITY CRITERIA, MONITORING, DOSE DELAYS AND MODI FICATIONS  
5.1 Toxicity Criteria 
This study will utilize the CTCAE version 5  for toxicity and Adverse Event Reporting.  A copy of 
the CTCAE version 5 .0 can be downloaded from the CTEP home page (http://ctep.cancer.gov). 
All appropriate treatment areas should have access to a copy of the CTCAE version 5.0.  
5.2 Dose Delays 
Major Events are grade 3 and 4 hematologic and non-hematologic toxicities  that are not 
treatment -related. Treatment should be delayed for major events if it  may further complicate the 
Version Date: 11 -30-2021  UPCC 21520  
14 
 non-treatment related event.  If a major event requires a delay of treatment, treatment must be 
delayed until toxicity is resolved (≤ Grade 2 or ≤ Baseline). For treatment-related toxicities and 
major events, i f toxicity is not resolved in ≤  28 days , patient will be taken off treatment, unless 
there is an exception granted by the medical monitor .   
5.3 Toxicities and Dose Modifications  
Guidelines for specific toxi cities are outlined below, but general guidelines for toxicities not listed 
are provided in Table 5. Of note, if a toxicity is attributable only to one of the investigational 
drugs, the other investigational agent can be continued if tolerated. 
 
General Dose modification guidelines for binimetinib for toxicities attributable to only 
binimetinib.  These are general guidelines but for specific toxicities dose modification 
instructions may be different  Doses of binimetinib should be adjusted for AEs  throughout the 
study (see Table 1  Recommended Dose Levels ). In general, doses should not be reduced or 
interrupted for Grade 1 AEs unless the AE is a specific ocular AE referred to in the 
Recommended Dose Modifications Table (see Table 2)  but treatment to control symptoms 
should be provided as appropriate, if applicable.  
 
An individual patient may have their dose of binimetinib reduced to the dose levels in Table 1  
below: 
 
Table 1    Recommended Dose Levels 
 Binimetinib  
(mg BID)  
Starting Dose  45 
 
Dose Level -1 30 
 
Dose Level -2 15 
 
The lowest recommended dose level of binimetinib is 15 mg BID. When the AE that resulted in 
a dose reduction improves to and remains stable at the patient’s baseline level for a minimum of 
14 days, the dose can be re -escalated to the next dose level at the discretion of the Investigator, 
provided there are no other concomitant toxicities that would prevent drug re-escalation. There 
is no limit to the number of times the patient can have their dose reduced or re-esca lated, 
however:  
• No dose re-escalation of binimetinib is allowed after a dose reduction due to LVEF 
dysfunction  
• No dose re-escalation of binimetinib is allowed after a dose reduction due to retinal toxicity ≥ Grade 2. 
Please refer to Dose Modification Tabl e for recommended dose modifications for binimetinib, if 
applicable, based on the occurrence of treatment-related AEs.  
 
 
  
 
Version Date: 11 -30-2021  UPCC 21520  
15 
 Table 2 Recommended Dose Modifications  
In all cases except retina disorders, HCQ may be continued at the discretion of the treating physician  
 
      Severity of Adverse Event        Dose Modifications  
Cardiomyopathy  
Asymptomatic, absolute decrease in 
LVEF of > 10% from baseline that is also 
below the LLN  Withhold binimetinib for up to 4 weeks, evaluate 
LVEF every 2 weeks.  
Resume binimetinib at a reduced dose if the 
following are present:  
• LVEF is at or above the LLN and 
• Absolute decrease from baseline is 10% or less and  
• Patient is asymptomatic. 
If LVEF does not recover within 4 weeks permanently discontinue binimetinib.  
Grade 3 -4 (Symptomatic congestive 
heart failure or absolute decrease in LVEF of > 20% from baseline that is also 
below LLN)  Permanently discontinue binimetinib. Closely 
monitor LVEF until resolution or up to 16 weeks.  
Venous Thromboembolism  
Uncomplicated DVT or PE  Withhold binimetinib.  
• If improves to Grade 0-1, resume at a reduced dose.  
• If no improvement, permanently discontinue 
binimetinib.  
Life threatening PE  Permanently discontinue binimetinib.  
Serous Retinopathy  
Symptomatic serous retinopathy/ Retinal 
pigment epithelial detachments  Withhold binimetinib for up to 10 days.  
• If improves and becomes asymptomatic, resume at the same dose. 
• If not improved, resume at a lower dose level 
or permanently discontinue binimetinib.  
Retinal Vein Occlusion (RVO ) 
Any Grade  Permanently discontinue binimetinib.  
Uveitis  
Grade 1 -3 If Grade 1 or 2 does not respond to specific ocular 
therapy, or for Grade 3 uveitis, withhold binimetinib for up to 6 weeks.  
• If improved, resume at same or reduced dose.  
• If not improved, permanently discontinue 
binimetinib.  
Grade 4  Permanently discontinue.  
Version Date: 11 -30-2021  UPCC 21520  
16 
       Severity of Adverse Event        Dose Modifications  
Other Eye Disorders (i.e., Non -retinal Events, non -Uveitis Events  
Grade 1 -2 Maintain dose level of binimetinib and increase 
frequency of ophthalmic monitoring to at least 
every 14 days until stabilization or resolution.  
Grade 3  Interrupt dosing of binimetinib and refer patient to 
ophthalmologist within 7 days. 
• If resolved to Grade ≤ 1 in ≤ 21 days, resume 
treatment at 1 reduced dose level of 
binimetinib.  
• If not resolved to Grade ≤ 1 in ≤ 21 days, 
permanently discontinue binimetinib and close 
follow -up with ophthalmic monitoring until 
stabilization or resolution.  
Grade 4  Permanently discontinue binimetinib and 
immediate follow -up with ophthalmic monitoring 
until stabilization or resolution.  
Interstitial Lung Disease  
Grade 2  Withhold binimetinib for up to 4 weeks.  
• If improved to Grade 0-1, resume at a reduced 
dose.  
• If not resolved within 4 weeks, permanently 
discontinue.  
Grade 3 or Grade 4  Permanently discontinue.  
Hepatotoxicity  
Grade 2 AST or ALT increased  Maintain binimetinib dose.  
If no improvement within 2 weeks, withhold 
binimetinib until improved to Grade 0-1 or to 
pretreatment/baseline levels and then resume at 
the same dose.  
Grade 3 or 4 AST or ALT increased  See Other Adverse Reactions  
Rhabdomyolysis or Creatine Phosphokinase (CPK) elevations  
Grade 4 asymptomatic CPK elevation or  
Any Grade CPK elevation with symptoms or with renal impairment  Withhold binimetinib dose for up to 4 weeks.  
If improved to Grade 0-1 resume at a reduced 
dose.  
If not resolved within 4 weeks, permanently 
discontinue binimetinib.  
Dermatologic  
Grade 2  If no improvement within 2 weeks, withhold until 
Grade 0-1. Resume at same dose if first 
occurrence or reduce dose if recurrent.  
Grade 3  
 
 
 
Grade 4  Withhold until Grade 0 -1. Resume at same dose if 
first occurrence or reduce dose if recurrent. If 
recurrent and already on dose level - 2, resume at 
that dose.  
Permanently discontinue  
Nausea/Vomiting   
Grade 1 -2 Maintain dose level of binimetinib. Promptly 
institute antiemetic measure. 
Version Date: 11 -30-2021  UPCC 21520  
17 
       Severity of Adverse Event        Dose Modifications  
Grade 3  Interrupt dosing of binimetinib until resolved to 
Grade ≤ 1. Then resume treatment at 1 reduced 
dose level of binimetinib. Resume treatment with 
binimetinib at the current dose if, in the judgment 
of the Investigator, the toxicity is considered to be 
unrelated to binimetinib, or at 1 reduced dose level. 
Note: Interrupt dosing of binimetinib for ≥  Grade 3 
vomiting or Grade 3 nausea only if the vomiting or 
nausea cannot be controlled w ith optimal 
antiemetics (as per local practice).  
Grade 4  Permanently discontinue binimetinib.  
Other Adverse Reactions (including 
haemorrhage)   
Recurrent Grade 2 or  
First occurrence of any Grade 3 Withhold for up to 4 weeks.  
• If improves to Grade 0-1 or to 
pretreatment/baseline levels, resume at 
reduced dose. 
• If no improvement, permanently discontinue.  
First occurrence of any Grade 4  Permanently discontinue or withhold for up to 4 
weeks. 
• If improves to Grade 0-1 or to 
pretreatment/baseline levels, then resume at a 
reduced dose.  
• If no improvement, permanently discontinue.  
Recurrent Grade 3  Consider permanently discontinuing.  
Recurrent Grade 4  Permanently discontinue.  
 
Investigators should always err on the side of caution in these settings if treatment-related 
toxicity is a possibility. 
5.3.1 Ocular Toxicity  
Due to the known ocular toxicities associated with MEK inhibitors and the potential for toxicity 
with HCQ, ophthalmic exams  will be m andatory for all patients  until protocol treatment is 
discontinued, as indicated in study calendar . In addition, an ophthalmologist should be 
consulted if changes in vision develop.  However, if the visual changes are clearly unrelated to 
study treatment ( e.g., allergic conjunctivitis), then monitor closely as it may be reasonable to 
defer ophthalmic examination.  
 
Monitor patients for visual signs and symptoms (such as, change in vision, photophobia and eye 
pain) during therapy. Special attention should be given to retinal findings (e.g., retinal pigment 
epithelial detachment (RPED) or retinovascular abnormalities  (i.e., branch or central retinal vein 
occlusions (RVO).   
 
The ocular component of this clinical trial will be important in better understanding ophthalmic 
risk inherent to the drug combination. All key subjective complaints, exam findings and testing 
Version Date: 11 -30-2021  UPCC 21520  
18 
 data will be entered into a study specific case report form for analysis and summarization at the 
conclusion of the trial.  
Table  3   Ocular Examination timeline   
  Examination components1 
Timepoint2  Comprehensiv
e eye exam3 OCT  10-2 Humphrey 
visual fields  Fundus 
photography4 Fundus 
autofluorescence4 
Baselinea  X X X X X 
Cycle 2b X X    
Cycle 7b X X X   
Cycle 13c X X X X X 
Cycle 19c X X X   
Cycle 25d X X X X X 
End of studye X X X X X 
Footnotes (1 -4): 
1- to be performed OU in both eyes.  
2- if ophthalmic AE's are reported, an unscheduled exam should be performed including comprehensive exam and if 
clinically indicated, HVF 10 -2, macular OCT,  and fundus photos.  
3-To assure the ocular safety of the subjects, at each ocular exam visit the Ophthalmology sub -Investigator will 
perform a comprehensive eye examination of both eyes. The specified assessments within the ophthalmic examination are reflective of consensus guidelines [American Academy of Ophthalmology Preferred Practice 
Patterns Committee, 2005] and will be performed according to the Investigator’s usual practice in addition to the 
assessment of visual acuity in the study and will include:  
-Ocular alignment and motility, pupillary function, and visual fields by confrontation  
-External examination of the eyelids and eyelashes  
-Slit-lamp biomicroscopic examination of the anterior segment structures: eyelid margins, conjunctiva, sclera, cornea, 
anterior chamber, iris, lens, and anterior vitreous  
-Intraocular pressure (IOP) measurement  
-Following dilation of the pupil, continued slit -lamp biomicroscopic examination of anterior segment structures with 
clinical grading of lens opacity  
-Fundu s slit-lamp biomicroscopic examination, including use of accessory diagnostic lenses, to view the vitreous, 
retina, macula, vasculature, and optic nerve  
4-if changes on exam or ancillary testing are noted, fundus photography and autofluorescence should be utilized if 
clinically indicated.  
Footnotes (a -e) 
a- Within 56 days of starting therapy  
b- +/- 1 week to allow for scheduling difficulties  
c- +/- 2 weeks to allow for scheduling difficulties  
d- After  2 years patients will continue to be followed every six cycles ( months).  At the half -year follow- ups (e.g. 2.5 
y, 3.5 y, etc), exams will comprise the same components as the 1.5 y exam.  At the annual follow- ups (e.g. 3y, 
4y, etc), the exam will comprise the same components as the 2 year exam.  
e- If end of study occurs w ithin 3 cycles ( months) of the most recent scheduled exam, no additional testing is 
required unless ophthalmic concerns played a role in discontinuation in which case a full end of study exam is 
conducted. If end of study falls  outside of this timeframe, the end of study eye exam should be captured when 
feasible.  
 
 
 
Version Date: 11 -30-2021  UPCC 21520  
19 
 Table 4  Management and Dose Modification Guidelines for Visual Changes and/or 
Ophthalmic Examination Findings  
CTCAE Gradea Adverse Event Management  Action and Dose Modification  
  
Grade 1b • Consult ophthalmologist within 7 days 
of onset  
 • If dilated fundus examination cannot be 
performed within 7 days of onset, interrupt 
binimetinib and hydroxychloroquine until 
RVO , and visual field deficit  can be excluded 
by retina  specialist/ophthalmologist.   
• If and RVO excluded, continue (or restart) binimetinib and HCQ  at same dose level  
• If RVO diagnosed:   Permanently 
discontinue binimetinib and report as 
SAE.  
 
 Grade 2 and  
 Grade 3  • Consult ophthalmologist immediately  
• Interrupt binimetinib and HCQ .  • If RVO excluded,  restart binimetinib and 
HCQ at same dose level.  
• If RVO diagnosed:  Permanently 
discontinue binimetinib  and report as 
SAE 
  
Grade 4  • Consult ophthalmologist immediately  
• Interrupt binimetinib and HCQ .  • If  visual field deficit and RVO excluded,  may 
consider restarting binimetinib at same or 
reduced dose after discussion with study medical monitor  
• If RVO or visual field deficit  diagnosed, 
permanently discontinue binimetinib and 
report as SAE.  
Abbreviations:  RPED = retinal pigment epithelial detachment; CTCAE = Common Terminology Criteria for 
Adverse Events; RVO= retinal vein occlusion; SAE = serious adverse event  
a. Refers to CTCAE Version 5.0 ‘Eye disorders – Other, specify’  
b. If visual changes are clearly unrelated to study treatment (e.g., allergic conjunctivitis), monitor closely but 
ophthalmic examination is not required.  
 
Table 5 Recommended dose modifications for binimetinib for retinal pigment epithelial 
detachments ( RPED ) 
CTCAE Grade  Action and Dose Modification  
Grade  1 RPED 
(Asymptomatic; clinical or diagnostic 
observations only)  • Continue treatment with retinal evaluation each cycle ( monthly ) 
until resolution. If RPED worsens follow instructions below  
Grade  2-3 RPED 
(Symptomatic with  
mild to moderate 
decrease in visual 
acuity; limiting 
instrumental ADL)  • Interrupt binimetinib and hydroxychloroquine 
• Retinal evaluation each cycle ( monthly )  
• If improved to ≤ Grade 1, restart binimetinib at lower dose or 
discontinue in patients taking lowest dose 
Version Date: 11 -30-2021  UPCC 21520  
20 
 Table 6    Management of Ocular Toxi cities 
 
Ocular Toxicity  Uveitis, conjunctivitis  Retinal Vein occlusion, 
retinal pigment 
epithelial detachment 
(RPED), papilledema.  Visual field deficits  
 
Action  Continue all therapies 
as long as effective 
local therapies can 
control inflammation  See table 3, 4, 5   Discontinue HCQ  
 
5.3.2 Hydroxychloroquine Dose Reduction  
Any AE of ≥ Grade 3 and attributed as possibly, probably or definitely related solely to HCQ will 
result in the dose being held until the AE has resolved to ≤ grade 1 or baseline while binimetinib 
dosing may continue uninterrupted. If the AE resolves, reinstitution of treatment can occur but at a reduced dose as described in Table 5. If the AE recurs at the reduced dose, treatment will be 
held until the AE has resolved to ≤ grade 1 and when resolved treatment can be reinstituted at the next lower dose level. No more than 2 dose reductions are allowed during the maintenance 
cycles.  
  
Toxicities that may be attributable to HCQ include:  nausea, anorexia, vomiting, constipation, 
diarrhea, rash, and visual field deficit.  If any of these AEs occur at grade ≤ 2, HCQ may be 
continued and the AE managed with supportive care. For any AE with a grade ≥ 3, HCQ dose will be held until the toxicity resolves to ≤ grade 2, after which HCQ may be restarted at a 
reduced dose as described in table 5.  With particular regard to visual field deficits patients 
should be cautioned to report any visual symptoms, particularly di fficulty seeing entire words or 
faces, intolerance to glare, decreased night vision, or loss of peripheral vision. These 
symptoms of retinal toxicity or subclinical evidence of retinal toxicity on scheduled eye 
exams should prompt drug discontinuation and ophthalmologic evaluation.  
 
6.0 PHARMACEUTICAL INFOR MATION  
Array BioPharma Inc. is providing Binimetinib (Mektovi ®) in order to conduct this study.   
Hydroxychloroquine is commercially available. 
Drug accountability logs and pharmacy records must be maintained at each pharmacy location 
and must be available for review upon request. Drug accountability logs and pharmacy records 
will be reviewed during monitoring visits, and by the ACC Department of Compliance and 
Monitoring (DOCM) at the time of each audit.  
 
For complete information please refer to the package inserts at http://dailymed.nlm.nih.gov/dailymed/
 
 
6.1 Hydroxychloroquine  
Generic name:  Hydroxychloroquine sulfate 
Commercial name:  Plaquenil  
Chemical name:   7-Chloro-4 -[4-[ethyl -(2-hydroxyethyl)amino]-1 -methylbutylamino] 
quinolone  
Source:   Commercially available 
Version Date: 11 -30-2021  UPCC 21520  
21 
  
6.2 Binimetinib 
Generic name:   Binimeti nib  
Commercial name:  Mektovi  
Chemical name:   5-[(4-bromo- 2-fluorophenyl)amino]-4 -fluoro-N -(2 hydroxyethoxy) -1-
methyl -1H-benzimidazole-6 -carboxamide 
Source:  Study provided (see the Manual of Procedures for ordering instructions)  
 
Storage and Handling: Binimetinib film -coated tablets are packaged in plastic bottles or in 
blister packs acceptable for pharmaceutical use.   
• Binimetinib film -coated tablets packaged in plastic bottles should not be stored above 25 
degrees Centigrade and should be protected from the light 
• Binimetinib film -coated tablets packaged in opaque polyvinyl chloride 
(PVC)/polyviny lidene chloride (PVDC) blister packs do not require any specific storage 
conditions  
Binimetinib oral suspension prepared from 15 mg binimetinib tablets should not be stored above 
25 degrees Centigrade and should not be refrigerated.  The constituted suspension should be 
used within 30 days after preparation.  
Version Date: 11 -30-2021  UPCC 21520  
22 
 7.0 CORRELATIVE STUDIES  
7.1 Overview of Correlative Studies.  
A number of blood and tissue collections are involved in this study to address important 
research questions. For patients with safely biopsi able disease, a biopsy may be performed 
prior to study enrollment and again after 3 weeks of therapy.  This biopsy is encouraged, but 
optional.  We aim to have 5 patients undergo biopsy.  We will also collect plasma at each visit 
for autophagy biomarkers, whole blood for HCQ PK, and archival tumor tissue will be collected 
for all patients.  
Summary of timing for correlative study collections:  
I. HCQ PK : Pre-treatment  (baseline and/or C1D1 prior to therapy) , during combination therapy: at 
every cycle ( monthly ) visit 
II. Biopsy  (Optional ) at 
1) Baseline  
2) C1D21 ± 7 days  
III. Plasma for autophagy dynamics  (All enrolled subjects):  
1) Pre-treatment (baseline and/or C1D1 prior to therapy)  
2) D1 of each cycle for C1-4  
3) Sample obtained at progression  
IV. Archival tissue (All enrolled subjects)  
Obtain 20 unstained slides from archival FFPE  blocks  
Table 7 Blood collection schedule 
Sample 
Type  Pre-treatment  C1D1*  C2D1  C3D1  C4D1  CXD1  
Plasma  X X X X X  
HCQ PK  X X X X X X 
*At least one collection pre-treatment is required prior to C1D1 treatment, both time points are 
encouraged  
 
7.2 HCQ Pharmacokinetics 
7.2.1 Clinical Pharmacology of HCQ and rationale for population PK Studies  
Preclinical studies have demonstrated that high nanomolar to low micromolar concentrations of 
CQ or HCQ are needed to effectively inhibit autophagy resulting in the accumulation of AV in 
cancer cells. In order to characterize autophagy inhibition in patients r eceiving HCQ in 
combination B, PK measurements will be correlated with PD measurements to determine the 
exposure of HCQ that is clinically achievable in this population and the effect on autophagy at 
these concentrations.  Comparison of PK measurements  of HCQ when given in this 
combination regimen to previously reported PK measurements of HCQ alone, will also identify potential drug-drug interactions that require further study. All PK analyses will be done by Lisa 
Davis, PhD at the University of Arizona through a subcontract and MTA . 
 
The PK properties of HCQ as a single agent have been extensively described in patients with 
rheumatoid arthritis. In one study patients received HCQ at doses of 400 mg, 800 mg or 1200 
Version Date: 11 -30-2021  UPCC 21520  
23 
 mg po daily  (Carmichael et al., 2003) . HCQ is metabolized by the p450 enzyme system into a 
number  of active metabolites. The investigators measured the blood levels of HCQ, and its 
active metabolites desethylhydroxychloroquine (DHCQ), desethylchloroquine (DCQ) and 
bisdesethylchloroquine (BDCQ). Despite differences in interindividual PK measurements, H CQ 
concentration increased linearly in the blood of patients with dose. In this study peak 
concentrations of HCQ approach 2-3 μM in higher dose cohorts supporting the need for dose escalation of HCQ beyond the 400 mg po daily dose that is commonly prescribed for 
rheumatoid arthritis patients. A clear dose-response relationship was observed between peak 
HCQ, DHCQ, and BCQ concentrations and improvement in arthritis. In addition a clear 
association between peak HCQ concentrations and GI toxicity, mainly nausea and vomiting, 
was observed.   The mean elimination half-life of each of these metabolites is between 30-50 
days. Due to budgetary constraints binimetinib PK studies are not planned. If there is a 
significant difference between HCQ exposure in thi s study compared to previous studies and 
there is sufficient activity to warrant a larger phase II study a more complete drug-drug interaction study can be c onducted as part of that study. 
 A population PK approach has been used in the past for HCQ, and has several advantages 
compared to a more traditional intensive sampling PK study design.  First, it allows the analysis 
of relatively sparse data which can be more easily obtained over time in an outpatient setting. 
Furthermore, a population PK analysis provides estimates of population central PK parameter 
values, as well as estimates of inter - and intra-patient variability in HCQ blood concentrations. 
To obtain these estimates, samples must be obtained from each patient on more than one occasion. In patients that remain on study for this time, blood concentration determinations 
during the late phases of the study will be important to derive PK parameter estimates that are 
most representative of those at steady -state conditions. Samples obtained during initial and late 
phases of the study will be used to build the population PK model. 
7.2.2 Pharmacokinetic Sample Collections 
A sparse sampling approach will be applied to all patients  that consists of blood collection pre-
treatment, and monthly after start of B+HCQ .  A 5 mL venous blood sample for determination of 
HCQ in anticoagulated whole blood will be collected in a heparinized green-top tube and placed 
on ice until it can be aliquotted into three polypropylene tube and stored at -8 0oC.  
Centrifugation is not requi red.  All specimens will be labeled with the patient’s assigned study 
number, day on study, date and time. A separate log of patient samples will also record this 
information, and in addition, the time of last HCQ and last bini metinib dose, and time of las t 
meal, and a description of concomitant medications at the time of collection.  The PK blood 
draw should be scheduled for the convenience of the subject.  For these sparse sampling 
collections, patients will be asked to continue their drug dosing as scheduled and not hold any 
doses even on days of blood draws. For HCQ, one sample w ill be collected during each visit for 
the first year that will also ensure random collections at times both pre- and post-HCQ dose.  
The time of last administration of HCQ and the time of the blood draw should be recorded.  
7.2.3 Bioanalytic Methods and PK analysis.  
The bioanalytic method and pharmacokinetic analysis will be performed at the University of 
Arizona under the aegis of Lisa Davis, PhD.  
 
Hydroxychloroquine. Whole blood concentrations of HCQ and its metabolites (DHCQ, DCQ, 
BDCQ) will be measured using a modification of published high-performance liquid 
chromatography methods using fluorescence and tandem mass spectrometry detection (HPLC -
MS/MS). CQ will be used as the internal standard. Briefly, the blood will be alkalinized and then 
subjected to ether extraction to extract HCQ and its metabolites. The ether extracts will be 
Version Date: 11 -30-2021  UPCC 21520  
24 
 evaporated to dryness and reconstituted in mobile phase. A methanol -based mobile phase will 
be used to separate the analytes. Elution of the analytes will be analyzed simultaneously using fluorescence and mass detection with a Varian LC 1200 triple quadrupole mass spectrometer. 
Whole blood concentrations of HCQ  w ill be calculated for each sample based on a standard 
curve of peak area ratios of the drug and internal standard (CQ).  
 A population PK model will be developed to define the full HCQ PK profile over the entire patient 
population, which includes patients receiving HCQ in conjunction with other agents under 
investigation. In the population approach, data from individual patients are treated as random 
samples from a larger population.  Estimates of the population central values for HCQ, as well 
as inter - and intra-patient variability are determined using nonlinear mixed-effects modeling 
software (NONMEM). The population PK parameters that will be estimated using this approach are apparent clearance (Cl/F) and volume of distribution of the central compartment (Vd/F). 
Since the absolute bioavailability of HCQ (F) cannot be calculated for oral dosing alone, 
bioavailability will be represented by a fixed constant for each of the parameter estimates. 
Comparison of these PK parameters of HCQ when given in combination with D+T  to previously 
reported PK parameters of HCQ alone may identify a potential drug interaction that requires further study. 
 
The results from the population analysis will be used as prior information to obtain Bayesian 
estimates of each individual patient’s PK parameters (Cl and Vd) from his/her blood HCQ 
concentrations. The Bayesian approach incorporates data from a population pharmacokinetic 
model and each individual patient to estimate the patient’s pharmacokinetic parameters. The a 
priori pharmacokinetic parameters of the population model are used as a starting estimate for 
the individual’s parameters, which are then adjusted based on the patient’s measured drug 
levels and with consideration of the variability of the parameters and drug concentration measurements. With this approach, the population model itself is incorporated into the 
estimation procedure.  
 
This algorithm will determine the individual estimates of blood clearance (Cl/F) and volume of 
distribution (Vd/F) from which the following P K parameters of HCQ exposure in individual 
patients will be calculated:  1) area under the concentration-versus time curve (AUC) 2) peak (Cmax) blood concentrations. 3) trough (Cmin) blood concentrations. AUC will be computed as 
follows: AUC (mcg * h/mL) = Dose (mg)/Cl (L/h). The Cmin and Cmax levels will be derived from 
model -predicted concentrations just prior to and following a dose of HCQ, respectively. These 
data will be summarized by dose for the phase I portion of the trial and used for correlative 
toxicity and efficacy analyses.  
 
7.3 Pharmacodynamic Studies in tumor tissues 
7.3.1 Serial Tumor Biopsies and analysis.  
Optional  serial tumor biopsies are  included in the budget for this study . We anticipate that  5 
patients  will complete at least two serial biopsies  (10 total biopsies ).  Biopsy of easily accesible 
lesions that do not require radiological guidance will  be conducted either by the medical 
oncologists,  surgical oncologist, dermatologists or dermatological surgeons . The proc edures 
involved include:  excisional biopsies, excisions of large tumors in the operating room, and core 
needle biopsies.  For core needle biopsies we request 4 cores if possible.  The radiologist m ay 
choose the size of the needle.  Lesions that are not easily accesible can be biopsied with the 
assistance of imaging guidance. This will involve core needle biopsies conducted by a 
radiologist. Processing of cores will be as follows:  
Version Date: 11 -30-2021  UPCC 21520  
25 
 Core 1) formalin- provided by the institution’s pathology department. Sample is processed 
through surgical pathology. Once all samples are obtained, or at an intermediate 
timepoint in the study, a request for 20 unstained slides or the tissue block from this 
specimen will be made.  
Core 2) snap frozen.- handled by institutions path department. Samples should be stored at 
-80ºC  or in liquid nitrogen until batch shipment on dry ice.  
Core 3) EM fixative- provided by Dr. Amaravadi’s lab (please email 
ravi.amaravadi@Uphs.upenn.edu  to request EM fixative).  
A sesame seed size sample of tissue can be fixed in EM fix and stored at 4ºC  (regular 
refrigerator)  until batch shipment. 
Core 4) additional research sample  
Timepoints for serial tumor biopsies will be  
1) baseline  
2) C1D21 ± 7 days  
These timepoints may be changed/modified at the discretion of the prinicipal investigator /study 
chair since the precise timing of successfully measuring the biological effect of drug intervention 
is not known.   
7.3.2 Measuring autophagy induction and autophagy inhibition in tumor tissue. 
Currently the gold standard techniques for detection of autophagy in tissues are 1) electron microscopy (EM) and 2) immunoblotting against the autophagy protein LC3. The accumulation of characteristic double- membrane vesicles in cells can be quantified by EM. When autophagy 
is induced by cellular stresses, small AV can be detected with well -digested contents. When 
autophagy is inhibited with CQ derivatives, larger and more numerous AV with undigested contents accumulate. When AV vesicles accumulate, LC3 is cleaved to form LC3-I and LC3-II
39. 
LC3-II is inserted into the membranes of AV making it a specific marker for AV formation. The 
ratio between LC3I and LC3II as measured by immunoblotting reflects the number of AV accumulated.  The inhibition of autophagy with CQ derivatives leads to a rapid accumulation of 
AVs in tumor tissue. This can be measured by scoring the number of AV/cell by EM in tumor 
tissue
24.   
7.3.3 Therapy -induced gene expression changes in the tissue microenvironment .   
In order to best understand the mechanism of action, resistance and interaction with the tumor 
microenvironment for dabrafenib, trametinib and HCQ, mRNA expression analysis or proteomic 
analysis is best suited to provide a snapshot of each of these effec ts. We will use the 
Quantigene® platform ( http://www.panomics.com/index.php?id=product_6 ) because it is 
compatible with both fresh and FFPE tumor tissue. The array will be customized and enriched 
for genes associated with the inflammatory response, kinase signaling pathways, and stress 
response pathways such as the endoplasmic reticulum (ER) stress response and autophagy. We anticipate there will be a total of 10 tissue samples from  5  patients from the phase II trial 
including pre -treatment, on treatment that are large enough to warrant this sort of analysis .  
7.4 Blood based correlative studies 
7.4.1 Plasma biomarkers for autophagy dynamics  
Rationale: Recent published data suggests that autophag y is not only involved in degradation of 
dysfunctional proteins but also plays a role in the maturation and secretion of functional proteins 
as well. By profiling the tumor secretome in cell culture and mouse xenograft model ,  we have 
Version Date: 11 -30-2021  UPCC 21520  
26 
 identified a number of candidate proteins. These have been validated in human samples, and in 
vitro data demonstrate elevations in IL-8, Interleukin-1 Beta, LIF, DKK3, and FAM3C in high autophagy states compared to low autophagy states. (Kraya Autophagy 2015).  We therefore 
propose to analyze plasma concentrations of these proteins in the presence and absence of 
HCQ and compare them to the gold standard of electron microscopy. We can then determine 
whether these proteins would be useful as an non-invasive biomarker of autophagy dynamics . 
 
7.4.2 Methods for Collecting Plasma 
Supplies (to be purchased and maintained by each institution’s clinical research lab)  
• Purple top EDTA Blood Collection Tubes (for example, BD vacutainers catalog # 
366450)  
• Centrifuge with swinging bucket rotor  
• 15 ml polypropylene conical tubes (for example, Corning 430052, Fisher  cat #05-538 -
53D)  
• Sterile cryovials with writing surface (for example, Simport T311-2 or Fisher  #05-669-57)  
• 2ml, 5ml and 10 ml pipettes (for example, Fisher cat #13-678 -11C, 13-678-11D, 13-678-
11E)  
• Disposable transfer pipettes (for example, Fisher cat #13-711 -20) 
• Automatic pipet aid  
• Small ice bucket  
Plasma Collection Procedure 
1) At each time point, encourage filling of entire volume of 1 purple top EDTA tube:  
2) After collection, gently mix the blood by inverting the tube 8 to 10 times. Store vacutainer 
tubes upright at 4ºC until centrifugation. Blood samples should be centrifuged within 
three hours of blood collection.  
3) Centrifuge blood samples in a horizontal rotor (swing-out head) for 10 minutes at 1200 g 
(2500 rpm) at room temperature. 
4) After centrifugation, plasma layer will be at the top of the tube. Mononuclear  cells and 
platelets will be in a whitish layer, called the “buffy coat”, just under  the plasma and 
above the red blood cells  
5) Collect plasma l ayer into a second tube. Spin secondary tube at 1200 xg (2500 rpm) for 
5 mins. To remove remaining red blood cells.  
6) Aliquot plasma (~4 ml) into cryotubes (500 µ l per tube). 
7) Transfer to - 80 °C for archival storage. NOTE:  Time from blood draw until freezing 
should be less than 3 hrs. (if greater than 3 hrs., note time and flag samples, but do not 
discard). Do NOT  store blood at 4 ° C. 
Plasma Data points 
1. Date and time of blood collection  
2. Number and volume of aliquots prepared 
3. Date and time into -80ºC  
Version Date: 11 -30-2021  UPCC 21520  
27 
 4. Date and time of shipping 
5. Any freeze-thaw that occurs with a sample for any reason 6. Any variations or deviations from the SOP, problems, or issues  
 
7.4.3 FFPE archival tumor tissue for genetic analysis.  
For all patients enrolled, we plan to obtain 20 unstained slides from archival FFPE blocks of 
ideally the latest metastatic lesion that was biopsied. 10 slides will be submitted for M yseq® 
multiplex DNA sequencing using the Illumina Truseq Cancer Panel 
(http://www.illumina.com/products/truseq_amplicon_cancer_panel.ilmn
), which consists of 
46 oncogenes and tumor suppressor genes through the Center for Personalized Diagnostics at 
the Univers ity of Pennsylvania. This extensive characterization of common somatic mutations 
will potentially generate hypothesis that a genotype-therapeutic interaction exists for long term survivors treated with this regimen. In addition, tumor samples obtained at progression will also 
be subjected to Myseq sequencing to generate hypotheses of mechanisms of resistance to this 
combination. Archival tissue remaining from genetic analysis will be available for future studies 
focused on the ER stress response and autopha gy using IHC techniques. Similar next 
generation sequencing platforms at other institutions or from outside vendors may be used. Slides should be requested within the first 6 months of enrollment and shipped to the address 
provided in 8.3.1 in batches  on a periodic basis.  
   
Version Date: 11 -30-2021  UPCC 21520  
28 
  
8.0 STUDY CALENDAR  
Trial Period:  Treatment Cycles (28 days, study assessments 
planned for D1 of each cycle)  End of 
Treatment Post -Treatment  
Treatment Cycle/Title : Screening 
Visit  
1 2 3 4 5 6   Beyond 8 
Cycles12  
EOT Safety 
Follow -
up Follow Up Visits  Survival 
Follow -Up 
7 8 9+ 
Scheduling Window 
(Days): -28 to -1 
 ± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 3 At time of 
Discontinuation 30 days 
post 
EOT7 As per standard 
of care  post 
discon of 
treatment5 Every 12 
weeks5 
Informed Consent  X              
Inclus ion/Exclusion 
Criteria Assessment  X              
Demogr aphics and 
Medical History  X              
Prior and Concomitant 
Medication Review  X X X X X X X X X X X X   
Drug  distribution   X 
 X 
 X 
 X 
 X 
 X 
 X 
 X 
 X 
  
       
Post-study anticancer 
therapy status            X X X X 
Surviv al Status               X 
Advers e Event 
Assessment  X X X X X X X X X X X X   
Full Physical 
Examination  X X X X X X X X X X X X   
Eye Exam14 X  X     X  X4     
EKG  X X X X X X X X X X     
Vital Signs and Weight  X X X X X X X X X X X X   
ECOG Performance 
Status  X X X X X X X X X X X X   
Pregna ncy Test – Urine 
or Serum β -HCG3 X X             
PT/INR and aPTT  X11              
CBC with Differential10 X11  X X X X X X X X X X X  
Version Date: 11 -30-2021  UPCC 21520  
29 
 Trial Period:  Treatment Cycles (28 days, study assessments 
planned for D1 of each cycle)  End of 
Treatment Post -Treatment  
Treatment Cycle/Title : Screening 
Visit  
1 2 3 4 5 6   Beyond 8 
Cycles12  
EOT Safety 
Follow -
up Follow Up Visits  Survival 
Follow -Up 
7 8 9+ 
Scheduling Window 
(Days): -28 to -1 
 ± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 3 At time of 
Discontinuation 30 days 
post 
EOT7 As per standard 
of care  post 
discon of 
treatment5 Every 12 
weeks5 
Compre hensive Serum 
Chemistry Panel10 X11  X X X X X X X X X X X  
Transthoracic Echo  X   X4   X4  
  X4     
Tumor Imaging6 X8  X9  X
9  X9  X9 X9 X  X13  
Tumor biopsies1 X X             
Research Blood 
Collection2 X X X X X X X X X X X    
1. On-study tumor tissue collection is optional and should be performed prior to treatment and then at C1D21±7 days  . Preference will be made to biopsy the 
same site for both biopsies, if safe and feasible.  
2. Up to 60mL of blood will be collected for research studies. Please refer to the Study Laboratory Manual for additional details.  
3. Female subjects of reproductive potential only.  A negative pregnancy test is required within 72 hours of Cycle 1/Day 1.  
4. Required q12  weeks (i.e. approximately every 3 cycles).  ECHO to be performed between D21 -D28 for applicable cycle  
5. Subjects who discontinue study treatment in the absence of disease progression will have post -treatment follow- up as per standard of care  for disease status 
until one of the following events: (1) disease progression; (2) initiation of non -study cancer treatment; (3) withdrawal of study consent; (4) loss to follow-up; or 
(5) death.  The subject will then enter into survival follow- up. Subjec ts who discontinue study treatment due to disease progression or initiation of a new anti-
cancer therapy will enter survival follow- up directly. Survival follow- up will continue up to 1 year from initation of study treatment (Cycle 1/Day 1).  
6. RECIST 1.1 will be used in this study for assessment of tumor response. While either CT or MRI may be utilized, as per RECIST 1.1, CT is t he preferred 
imaging technique in this study.  Tumor imaging timing should follow calendar days and should not be adjusted for delay s in cycle starts or extension of cycle 
duration.  All visceral areas originally involved by tumor should be re -imaged at each scan interval. The preferred type of imaging is high resolution CT scans 
of the chest abdomen and pelvis with contrast. In cases of elevated creatinine or anaphylactic reaction to contrast dye, CT scans without contrast or MRI with 
gadolinium may be substituted for the abdomen and non -contrast CT for the chest.  
7. The 30 day Safety Follow-up Visit must occur prior to the first dose of any new anti-cancer therapy.  
8. Baseline tumor imaging to be performed within 30 days prior to Cycle 1/Day 1  
Version Date: 11 -30-2021  UPCC 21520  
30 
 9. Tumor imaging to be performed after every 2 cycles(approximately every 2 months  after C1D1 on D21 -D28 of applicable cycle).  
10. CBC with differential in cluding hemoglobin, white blood count, absolute neutrophil count, and platelet count.  Serum chemistries including sodium (Na ), 
potassium (K), chloride (Cl), bicarbonate (HCO3), blood urea nitrogen (BUN), creatinine (Cr), albumin, total bilirubin, AST, ALT, and alkaline phosphatase.   
After Cycle 1, pre- dose laboratory procedures can be conducted up to 72 hours prior to dosing.  Results must be reviewed by the investigator or qualified 
designee and found to be acceptable prior to each dose of trial treatment .  
11. Screening laboratory tests are to be performed within 10 days prior to Cycle 1/Day 1.  
12. Treatment will continue indefinitely in the absence of (1), documented disease progression, (2) unacceptable adverse event(s) , (3) intercurrent illness that 
prevents further administration of treatment, (4) investigator’s decision to withdraw the subject, (5) subject withdrawal of consent, (6) pregnancy of the subject, 
(7) noncompliance with trial treatment or procedure requirements, (8) institution of alternative syst emic treatment, or (9) other administrative reasons.  
13. Tumor imaging in post -treatment follow- up will be performed per routine care and at the discretion of the treating investigator.  
14. See table 3 for required time -points. Suspicion for eye toxicity will prom pt an unscheduled research eye exam . To assure the ocular safety of the subjects, at 
each ocular exam visit the Ophthalmology sub -Investigator will perform a comprehensive eye examination of both eyes. The specified assessments within the 
ophthalmic examin ation are reflective of consensus guidelines [American Academy of Ophthalmology Preferred Practice Patterns Committee, 2005] and will 
be performed according to the Investigator’s usual practice in addition to the assessment of visual acuity in the study an d will include:  
-Ocular alignment and motility, pupillary function, and visual fields by confrontation  
-External examination of the eyelids and eyelashes  
-Slit-lamp biomicroscopic examination of the anterior segment structures: eyelid margins, conjunctiva,  sclera, cornea, anterior chamber, iris, lens, 
and anterior vitreous  
-Intraocular pressure (IOP) measurement  
-Following dilation of the pupil, continued slit -lamp biomicroscopic examination of anterior segment structures with clinical grading of lens opacity  
-Fundus slit -lamp biomicroscopic examination, including use of accessory diagnostic lenses, to view the vitreous, retina, macula, vasculat ure, and 
optic  nerve  
-if changes on exam or ancillary testing are noted, fundus photography and autofluorescence should be utilized if clinically indicated.  
 
To account for major holidays and unforeseen events such as inclement weather, scheduled visits and testing can occur +/- 1 week , 
as long as there is documentation as to why they did not occur according to intended schedule. Archival tumor tissue can be 
obtained at any point during study enrollment and treatment timeline 
 
Version Date: 11 -30-2021  UPCC 21520  
31 
 9.0 MEASUREMENT OF EFFEC T 
For the purposes of this study, patients should be re-evaluated for response every 2 cycles .  In 
addition to a baseline scan, confirmatory scans should also be obtained (not less than 4) weeks 
following initial documentation of objective response. 
Response and progression will be evaluated in this study using the new international criteria 
proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline 
(version 1.1) [Eur J Ca  45:228-247, 2009]. Investigator assessment of RECIST response will 
be used to make treatment decisions in real time. Scans will also be submitted for 
independent radiology review by the RECIST core in batches quarterly to provide an 
independent measure of response for research purposes. The investigator assessments and 
the independent radiology assessments will be reported separately.   Changes in the lar gest 
diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria. 
9.1 Definitions 
Evaluable for toxicity .  All patients will be evaluable for toxicity from the time of their first 
treatment with combined treatment with B and HCQ.  
 
Evaluable for objective response.  Only those patients who have measurable disease present at 
baseline, have received at least one cycle of therapy, and have had their disease re-evaluated 
will be considered evaluable for response.  These patients will have their response classified 
accor ding to the definitions stated below.  (Note:  Patients who exhibit objective disease 
progression prior to the end of cycle 1 will also be considered evaluable.)  
9.2 Disease Parameters  
Measurable disease.  Measurable lesions are defined as those that can be ac curately measured 
in at least one dimension (longest diameter to be recorded) as > 20 mm by chest x -ray, as > 10 
mm with CT scan, or > 10 mm with calipers by clinical exam.  All tumor measurements must be 
recorded in millimeters  (or decimal fractions of centi meters). 
Note :  Tumor lesions that are situated in a previously irradiated area are not considered 
measurable.   
 
Malignant lymph nodes.  To be considered pathologically enlarged and measurable, a lymph 
node must be > 15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm).  At baseline and in follow -up, only the short axis will 
be measured and followed. 
 
Non-measurable disease.  All other lesions (or sites of disease), including small lesions (longest 
diameter <10 mm or pathological lymph nodes with ≥ 10 to <15 mm short axis), are considered 
non-measurable disease.  Bone lesions, leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses 
(not followed by CT or MRI), are considered as non-measurable. 
Note :  Cystic lesions that meet the criteria for radiographically defined simple cysts should not 
be considered as malignant lesions (neither measurable nor non-measurable) si nce they are, by 
definition, simple cysts.  
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, if they meet the definition of measurability described above. However, if non-cystic 
lesions are present in the sam e patient, these are preferred for selection as target lesions.  
Target lesions.  All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target lesions and recorded 
Version Date: 11 -30-2021  UPCC 21520  
32 
 and measured at baseline.  Target lesions should be selected on the basis of their size (lesions 
with the longest diameter), be representative of all involved organs, but in addition should be 
those that lend themselves to reproducible repeated measurements.  It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement in which 
circumstance the next largest lesion which can be measured reproducibly should be selected.  
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum diameters.  If lymph nodes are to be 
included in the sum, then only the short axis is added into the sum.  The baseline sum 
diameters will  be used as reference to further characterize any objective tumor regression in the 
measurable dimension of the disease. 
 
Non-target lesions .  All other lesions (or sites of disease) including any measurable lesions over 
and above the 5 target lesions should be identified as non-target lesions and should also be 
recorded at baseline.  Measurements of these lesions are not required, but the presence, 
absence, or in rare cases unequivocal progression of each should be noted throughout follow -
up.  
9.3 Methods for Evaluation of Measurable Disease 
All measurements should be taken and recorded in metric notation using a ruler or calipers.  All 
baseline evaluations should be performed as closely as possible to the beginning of treatment 
and never more than 4 weeks before the beginning of the treatment. 
 
Clinical lesions .  Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and ≥ 10 mm diameter as assessed using 
calipers (e.g., skin nodules).  In the case of skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is recommended.  
 
Chest x -ray.  Lesions on chest x -ray are acceptable as measurable lesions when they are 
clearly defined and surrounded by aerated lung.  However, CT is preferable.  
 
Conventional CT and MRI.   This guideline has defined measurability of lesions on CT scan 
based on the assumption that CT slice thickness is 5 mm or less.  If CT scans have slice 
thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the 
slice thickness.  MRI is also acceptable in certain situations (e.g. for body scans).   
 
9.4 Response Criteria  
9.4.1 Evaluation of Target Lesions 
Complete Response (CR) : Disappearance of all target lesions.  Any pathological lymph 
nodes (whether target or non-target) must have reduction in short axis to <10 mm.  
 
Partial Response (PR) : At least a 30% decrease in the sum of the diameters of target 
lesions, taking as reference the baseline sum diameters  
 
Progres sive Disease (PD) : At least a 20% increase in the sum of the diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is 
the smallest on study).  In addition to the relative increase of 20%, the sum  must also 
demonstrate an absolute increase of at least 5 mm.  (Note:  the appearance of one or more new 
lesions is also considered progressions). 
 
Version Date: 11 -30-2021  UPCC 21520  
33 
 Stable Disease (SD) : Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for P D, taking as reference the smallest sum diameters while on study  
9.4.2 Evaluation of Non-Target Lesions 
Complete Response (CR)   Disappearance of all non-target lesions and normalization of tumor 
marker level.  All lymph nodes must be non-pathological in size (<10 mm short axis)  
Note:  If tumor markers are initially above the upper normal limit, they must normalize for a 
patient to be considered in complete clinical response.  
 
Non-CR/Non -PD:  Persistence of one or more non-target lesion(s) and/or maintenance of tumor 
marker level above the normal limits  
 
Progressive Disease (PD) :  Appearance of one or more new lesions and/or unequivocal 
progression of existing non-target lesions.  Unequivocal progression should not normally trump 
target lesion status.  It must be r epresentative of overall disease status change, not a single 
lesion increase.     
 Although a clear progression of “non- target” lesions only is exceptional, the opinion of the 
treating physician should prevail in such circumstances, and the progression status should be 
confirmed at a later time by the review panel (or Principal Investigator).  
9.4.3 Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for progressive disease the smallest 
measurements recorded since the treatment started).  The patient's best response assignment 
will depend on the achievement of both measurement and confirmation criteria.  
 
Table 8  Determination of Best Overall Response 
Target 
Lesions Non-Target 
Lesions New 
Lesions Overall 
Response Best Overall Response 
when Confirmation is 
Required*  
CR CR No CR >4 wks. Confirmation**  
CR Non-CR / Non-PD No PR  
>4 wks. Confirmation**  CR Not evaluated  No PR 
PR Non-CR / Non-PD / 
not evaluated  No PR 
SD Non-CR / Non-
PD/not evaluated No SD documented at least 
once >4 wks. from 
baseline**  
PD Any Yes or No  PD  
no prior SD, PR or CR  Any PD***  Yes or No  PD 
Any Any Yes PD 
*      See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.  
**    Only for non -randomized trials with response as primary endpoint.  
***  In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as disease 
progression.  
Note:  Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of 
disease progression at that time should be reported as “ symptomatic deterioration.”   Every effort should be made to document 
the objective progression even after discontinuation of treatment.  
Version Date: 11 -30-2021  UPCC 21520  
34 
 9.4.4 Duration of Response 
Duration of overall response:  The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date that 
recurrent or progressive disease is objectively documented (taking as reference for progressive 
disease the smallest measurements recorded since the treatment started). 
 The duration of overall CR is measured from the ti me measurement criteria are first met for CR 
until the first date that progressive disease is objectively documented. 
 
Duration of stable disease:  Stable disease is measured from the start of the treatment until the 
criteria for progression are met, taking as reference the smallest measurements recorded since 
the treatment started, including the baseline measurements.  
9.4.5 Progression-Free Survival  
PFS is defined as the duration of time from start of treatment to time of first progression, death 
due to any cause or last patient contact alive and progression-free.  In patients treated beyond 
progression, time to first progression (isolated) and second progression (multifocal) will be 
recorded.  
9.4.6 Overall Survival 
OS is defined as the duration of time from start of treatment to time of death due to any cause or last patient contact alive.   
9.4.7 Off treatment/Off Study  
Each subject has the right to withdraw from the study at any time without prejudice.  The 
investigator may discontinue any subject’s participation for any reason, including adverse event 
or failure to comply with the protocol.  Should a subject withdraw from the study, the reason(s) 
must be stated on the case report form, and a final evaluation of the subject should be 
performed. Reasons for withdrawal from treatment include the following:  
 
Progression of Disease:  Remove patient from protocol therapy at the time progressive disease 
is documented. 
 
Extraordinary Medical Circumstance: If at any time the treating physician feels constraints of this 
protocol ar e detrimental to the patient’s health remove the patient from protocol therapy.  
 
Patient’s refusal to continue treatment: In this event, document the reason(s) for withdrawal.  
Failure to comply with protocol (as judged by the investigator such as compliance below 80%, 
failure to maintain appointments, etc.).  Delay in treatment > 28  days due to toxicity  
 
Patients may also be removed from the trial after completing all relevant trial related 
procedures.  
 
10.0    ADVERSE EVENTS AND REPORTING  
The timely reporting of adverse events (including toxic deaths) is required by the Food and Drug 
Administration.  The reporting of toxicities is part of the data reporting for this study.   The 
investigator is responsible for ensuring that all adverse events ( AEs) and significant adverse 
Version Date: 11 -30-2021  UPCC 21520  
35 
 events ( SAEs ) that are observed or reported during the study, are collected and reported to the 
FDA, appropriate IRB(s), and Array  in accordance with CFR 312.32 (IND Safety Reports).  
10.1   Adverse Events 
An adverse event  (AE) is any symp tom, sign, illness or experience that develops or worsens in 
severity during the course of the study.  Intercurrent illnesses or injuries should be regarded as 
adverse events.  Abnormal results of diagnostic procedures are considered to be adverse 
events i f the abnormality: 
• results in study withdrawal  
• is associated with a serious adverse event 
• is associated with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests  is considered by the 
investigator to be of clinical signifi cance  
Adverse Event Reporting Period 
The study period during which adverse events must be reported is defined as the period from 
the initiation of the first study treatment to 30 days following the last administration of study 
treatment. 
 
Post -study Adverse Event.  
All unresolved adverse events should be followed by the investigator until the events are 
resolved, the patient is lost to follow -up, or the adverse event is otherwise explained. At the last 
scheduled visit, the investigator should instruct each patient to report any subsequent event(s) 
that the patient, or the patient’s personal physician, believes might reasonably be related to 
participation in this study.  
 
Abnormal Laboratory Values. 
A clinical laboratory abnormality should be documented as an adverse event if the abnormality 
is of a degree, typically at least grade 2 and not present as grade 1 or better at baseline, that 
requires active management; e.g. change of dose, discontinuation of the drug, more frequent 
follow -up assessments, further diagnostic investigation.  
10.2    Recording of Adverse Events.  
At each contact with the subject, the investigator must seek information on adverse events by specific questioning and, as appropriate, by examination.  Information on all adverse events 
should be r ecorded immediately in the source document, and also in the appropriate adverse 
event module of the case report form (CRF).  All clearly related signs, symptoms, and abnormal 
diagnostic procedures results should be recorded in the source document, though s hould be 
grouped under one diagnosis.  
 
All adverse events occurring during the study period must be recorded. The clinical course of 
each event should be followed until resolution, stabilization, or until it has been determined that 
the study treatment or participation is not the cause.  Seriou s adverse events that are still 
ongoing at the end of the study period must be followed up to determine the final outcome.  Any 
serious adverse event that occurs after the study period and is considered to be at least 
possibly related to the study treatment or study participation should be recorded and reported 
immediately. 
 
 
Version Date: 11 -30-2021  UPCC 21520  
36 
 10.2.1 Serious Adverse Events 
Adverse events are classified as serious or non-serious.   
 
A serious adverse event is any AE that is:  
• fatal 
• life-threatening 
• requires or prolongs hospital stay  
• results in persistent or significant disability or incapacity  
• a congenital anomaly or birth defect  
• an important medical event 
Important medical events are those that may not be immediately life threatening, but are clearly 
of major clinical significance.   They may jeopardize the subject, and may require intervention to 
prevent one of the other serious outcomes noted above.  For example, drug overdose or abuse, a seizure that did not result in in-patient hospitalization, or intensive treatment of bronchospasm 
in an emergency department would typically be considered serious.  
 
All adverse events that do not meet any of the criteria for serious should be regarded as 
non-serious adverse events.  
 
Events of progression of the subject’s underlying cancer as well  as events clearly related to 
progression of the subject’s cancer (signs and symptoms of progression) should not be reported 
as a serious adverse event.  
 
Hospitalization, Prolonged Hospitalization or Surgery.  
Any adverse event that results in hospitalizat ion or prolonged hospitalization should be 
documented and reported as a serious adverse event unless specifically instructed otherwise in 
this protocol. Any condition responsible for surgery should be documented as an adverse event if the condition meets the criteria for an adverse event. 
 
Neither the condition, hospitalization, prolonged hospitalization, nor surgery are reported as an 
adverse event in the following circumstances:  
• Hospitalization or prolonged hospitalization for diagnostic or elective surgi cal procedures 
for a preexisting condition. Surgery should not be reported as an outcome of an adverse 
event if the purpose of the surgery was elective or diagnostic and the outcome was 
uneventful. 
• Hospitalization or prolonged hospitalization required to allow efficacy measurement for the study. 
• Hospitalization or prolonged hospitalization for therapy of the target disease of the study, 
unless it is a worsening or increase in frequency of hospital admissions as judged by the 
clinical investigator.  
 
10.3    Assessment of Adverse Events 
All AEs and SAEs whether volunteered by the subject, discovered by study personnel during 
questioning, or detected through physical examination, laboratory test, or other means will be reported appropriately.  
Version Date: 11 -30-2021  UPCC 21520  
37 
 The severity rating of an AE refers to its intensity. The severity of each AE will be 
determined by the Investigator using the NCI CTCAE (cite version here). For any term that is 
not specifically listed in the CTCAE scale, severity should be assigned a Grade of 1 through 
5 usi ng the following CTCAE guidelines: 
 Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated 
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age 
appropriate instrum ental activities of daily living 
Grade 3: Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self-
care activities of daily living 
Grade 4: Life-threatening consequences; urgent intervention indicated 
Grade 5: Fatal  
 
Each reported AE or SAE will be described by its duration (i.e., start and end dates), regulatory 
seriousness criteria if applicable, suspected relationship to the study drug (see following guidance), and actions taken. To ensure consistency of AE and SAE causality assessments, 
only the PI or sub-investigators may grade AEs, and investigators should apply the following 
general guideline:  
 
10.3.1 Relationship to study drug: Yes  
There is a plausible tempor al relationship between the onset of the AE and administration of the 
study drug, and the AE cannot be readily explained by the subject’s clinical state, intercurrent 
illness, or concomitant therapies; and/or the AE follows a known pattern of response to the 
study drug; and/or the AE abates or resolves upon discontinuation of the study drug or dose 
reduction and, if applicable, reappears upon re-challenge.  
10.3.2 Relationship to study drug: No  
Evidence exists that the AE has an etiology other than the study drug ( e.g., preexisting medical 
condition, underlying disease, intercurrent illness, or concomitant medication); and/or the AE has no plausible temporal relationship to study drug administration (e.g., cancer diagnosed 2 
days after first dose of study drug).  
Suspected unexpected serious adverse reactions (SUSARs) will be collected and reported by 
the Sponsor and/or designee to the competent authorities and relevant ethics committees in 
accordance with Directive 2001/20/EC or as per national regulatory requirements in participating 
countries.  
 
Expected adverse events are those adverse events that are listed or characterized in the 
Package Insert or current Investigator Brochure.  
 
Unexpected adverse events are those not listed in the Package Insert (P.I.) or current 
Investigator Brochure (I.B.) or not identified. This includes adverse events for which the 
specificity or severity is not consistent with the description in the P.I. or I.B. For example, under 
this definition, hepatic necrosis would be unexpected i f the P.I. or I.B. only referred to elevated 
hepatic enzymes or hepatitis.  
Version Date: 11 -30-2021  UPCC 21520  
38 
 10.3.3 Diagnosis vs. Signs and Symptoms 
If known at the time of reporting, a diagnosis should be reported rather than individual signs and symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated 
transaminases). However, if a constellation of signs and/or symptoms cannot be medically 
characterized as a single diagnosis or syndrome at the time of reporting, it is ok to report the 
information that i s currently available. If a diagnosis is subsequently established, it should be 
reported as follow -up information. 
10.3.4 Deaths 
All deaths that occur during the protocol -specified AE reporting period (see Section 10.2), 
regardless of attribution, will be reported to the appropriate parties. Of note, if a death occurs due to progression without an accompanied adverse event, reporting to the drug manufacturer 
is not required.  When recording a death, the event or condition that caused or contributed to 
the fatal outcome should be reported as the single medical concept. If the cause of death is 
unknown and cannot be ascertained at the time of reporting, report “Unexplained Death”. 
10.3.5 Preexisting Medical Conditions 
A preexisting medical condition is one that is present at the start of the study. Such conditions 
should be reported as medical and surgical history. A preexisting medical condition should be re-assessed throughout the trial and reported as an AE or SAE only if the frequency, severity, or 
character of the condi tion worsens during the study. When reporting such events, it is important 
to convey the concept that the preexisting condition has changed by including applicable descriptors (e.g., “more frequent headaches”).  
10.3.6 Pregnancy  
Pregnancy itself is not regarded as  an AE unless there is a suspicion that the study medication 
may have interfered with the effectiveness of the contraceptive medication. If a female subject 
becomes pregnant while receiving investigational therapy or within 120 days after the last dose 
of study drug, a report should be completed and submitted to Array  within 24 hours of learning 
of its occurrence.   
 
Subjects who become pregnant during the study will not receive any additional study medication 
and will be withdrawn from the study.  The Inve stigator must strongly encourage these subjects 
to return to the study site for the final protocol -specified visit and assessments.  Follow -up to 
obtain the outcome of the pregnancy should also occur. Abortion, whether accidental, 
therapeutic, or spontaneous, should always be classified as serious, and expeditiously reported as an SAE. Similarly, details of the birth, and the presence or absence of any congenital 
anomaly/birth defect or maternal and/or newborn complications  in a child born to a female 
subject exposed to the study drug should be reported as an SAE.  
10.4    SAE Reporting to Array   
All serious adverse events , regardless of suspected causality, occurring after the patient has 
provided the main informed consent and until at least 30 days after the patient has stopped study treatment must be reported to Array  within 24 hours of learning of its occurrence.  Send 
the completed, signed SAE report  to the oncology Array Drug Safety and Epidemiology (DS&E) 
department (Fax 
866-997-8322 ). 
 
Any serious adverse event that occurs after the 30 days study period should only be reported to Array  if the investigator suspects a causal relationship to the study treatment. Recurrent 
episodes, complications, or progression of the initial SAE must be reported as follow -up to the 
Version Date: 11 -30-2021  UPCC 21520  
39 
 original episode within 24 hours of the investigator receiving the follow -up information. An SAE 
occurring at a different time interval or otherwise considered compl etely unrelated to a 
previously reported one should be reported separately as a new event.  
 
Other reportable events:  
Deviations:  
An one-time accidental or unintentional deviation from the approved protocol, identified 
retrospectively, that in the opinion of the investigator or as defined by the protocol, placed one 
or more participants at increased risk, compromises the rights or welfare of subjects, and/or 
disrupts the study design, is considered a reportable event and must be reported to the Study 
Princi pal Investigator, Study Medical Monitor, IRB, and ACC DSMC within 5 business days of 
knowledge.  Principal Investigator and Medical Monitor approval/acknowledgement must be 
received first and included in with the IRB/DSMC submission. 
Deviations to protect subjects from immediate harm/danger should be reported immediately 
following the event to the entities outlined above. 
Exceptions:  
An exception is defined as a one-time, intentional action or process that departs from the IRB 
and CTSRMC approved study protocol, intended for one occurrence. AND this action disrupts 
the study progress, such that the study design or outcome (endpoints) may be compromised, or 
the action compromises the safety and welfare of study subjects (i.e. requests to enroll and/or 
treat s ubjects outside of the current protocol criteria).  Exceptions that meet this criteria will not 
be allowed unless reviewed and approved first by the Study Medical Monitor and the Study 
Principal Investigator/Sponsor -Investigator, and then subsequently by the ACC DSMC, and 
UPenn IRB prior to this subject being enrolled/treated.  PI/Sponsor -Investigator and Medical 
Monitor approval must be received first and included in with the IRB/DSMC submission. All entities should be given sufficient time to evaluate thi s request.  
 Examples of Exceptions/Deviations that require submission include:  
• Stopping rules that were not completed per protocol  
• Dosing errors  
Exceptions to eligibility , treatment/dosing, contraindicated treatment/therapies/interventions or 
safety tests  will not be approved. 
 
Events not deemed reportable as outlined above will require a PI assessment regarding study 
and/or safety impact.  This assessment should be documented appropriately. 
10.5    UPENN IRB Notification by Investigator -Sponsor  
The University of Pennsylvania IRB (Penn IRB) requires expedited reporting of those events 
related to study participation that are unforeseen and indicate that participants or others are at 
increased risk of harm.  The Penn IRB will not acknowledge safety reports or bulk  adverse 
event submissions that do not meet the criteria outlined below.  The Penn IRB requires 
researchers to submit reports of the following problems within 10 working days from the time the 
investigator becomes aware of the event: 
• Any adverse event (regardless of whether the event is serious or non-serious, on-site or 
off-site) that occurs any time during or after the research study, which in the opinion of 
the principal investigator is:  
Version Date: 11 -30-2021  UPCC 21520  
40 
 Unexpected (An event is “unexpected” when its specificity and sever ity are not accurately 
reflected in the protocol -related documents, such as the IRB -approved research protocol, any 
applicable investigator brochure, and the current IRB -approved informed consent document and 
other relevant sources of information, such as product labeling and package inserts.)  
AND  
Related to the research procedures (An event is “related to the research procedures” if in the 
opinion of the principal investigator or sponsor, the event was more likely than not to be caused 
by the research proc edures.)  
 
Deaths occurring for patients on-study and within 30 days of study drug administration that are 
considered unforeseen and indicates participants or others are at increased risk of harm (i.e. unexpected and probably/definitely related), must be reported to the IRB within 24 hours of 
notification.  
 
Copies of each report and documentation of IRB notification and receipt will be kept in the 
Clinical Investigator’s study file. 
 
For clinical drug trials, the following events are also reportable to the P enn IRB: 
• Any adverse experience that, even without detailed analysis, represents a serious 
unexpected adverse event that is rare in the absence of drug exposure (such as 
agranulocytosis, hepatic necrosis, Stevens -Johnson syndrome).  
• Any adverse event that would cause the sponsor to modify the investigators brochure, 
protocol or informed consent form, or would prompt other action by the IRB to assure protection of human subjects.  
• Information that indicates a change to the risks or potential benefits of the r esearch, in 
terms of severity or frequency. For example:  
− An interim analysis indicates that participants have a lower rate of response to 
treatment than initially expected. 
− Safety monitoring indicates that a particular side effect is more severe, or more 
frequent than initially expected.  
− A paper is published from another study that shows that an arm of your research 
study is of no therapeutic value. 
• Change in FDA safety labeling or withdrawal from marketing of a drug, device, or 
biologic used in a research protocol.  
• Breach of confidentiality  
• Change to the protocol taken without prior IRB review to eliminate apparent immediate hazard to a research participant.  
• Incarceration of a participant when the research was not previously approved under Subpart C and the investigator believes it is in the best interest of the subject to remain 
on the study. 
• Complaint of a participant when the complaint indicates unexpected risks or the 
complaint cannot be resolved by the research team.  
• Protocol violation (meaning an acci dental or unintentional deviation from the IRB 
approved protocol) that in the opinion of the investigator placed one or more participants 
at increased risk, or affects the rights or welfare of subjects.  
 
The IRB will accept other reports when the investigator is unsure whether the event should be 
reported, and the IRB will review such reports to determine whether the event meets the 
threshold for an unanticipated event presenting risk to the participant.  
Version Date: 11 -30-2021  UPCC 21520  
41 
 Office of Regulatory Affairs, Institutional Review Board  
3624 Market Street, Suite 301S, Philadelphia, PA  19104-6006 Phone: 215-573-2540 
Fax: 215-573-9438 
 
10.5.1 Reporting Process to IRB at Penn. 
Unanticipated problems posing risks to subjects or others as noted above will be reported to the 
Penn IRB using the form: “Unanticipated Problems Posing Risks to Subjects or Others Including 
Reportable Adverse Events” or as a written report of the event (including a description of the 
event with information regarding its fulfillment of the above criteria, follow -up/resolution and 
need for revision to consent form and/or other study documentation).  
 Copies of each report and documentation of IRB notification and receipt will be kept in the 
Clinical Investigator’s study file. 
10.5.2 FDA Notification by Investigator -Sponsor .  
This s tudy is IND exempt and reporting to the FDA is voluntary using a Med Watch 3500 or via 
the FDA’s website for voluntary reporting. 10.6    Medical Monitoring  
It is the responsibility of the Principal Investigator to oversee the safety of the study  at the site. 
This safety monitoring will include careful assessment and appropriate reporting of adverse 
events, as noted above, as well as the construction and impl ementation of a site data and safety 
monitoring plan.  Medical monitoring by an independent clinician , Dr. Reiss -Binder , Department 
of Medicine, Division of Hematology -Oncology will review comprehensive safety data at least bi -
annually. This will include a real -time review of unexpected and related SAEs and any deaths 
that are unexpected or occur from the start until 90 days from the last study treatment. The Medical Monitor will also be consulted in the case of exception requests or the evaluation of 
deviations that may compromise subject safety or disrupt the design of the study. This 
information will be communicated to the Medical Monitor via email and filed in the Regulatory 
Binder/Subject Chart appropriately. As applicable, correspondence will be included in IRB/ACC 
DSMC submission of these events . Dr. Reiss Binder  will be reached at 
Kim.Rei ssbinder@pennmedicine.upenn.edu
 . Ophthalmic safety concerns that develop during 
the study will be forwarded to Array  for review, as well as the independent medical monitor. 
10.7    Study Monitoring Plan 
This study will be monitored in accordance with the Cancer Center’s Clinical Trials Scientific 
Review and Monitoring Committee (CTSRMC) Plan, approved by NCI during the Core Grant’s 
most recent review. This plan requires that the investigator submit a study -specific plan outlining 
how data will be reviewed In addition, the CTSRMC plan calls for an internal audit by the 
Cancer Center’s Data Safety Committee twice yearly. The investigator will allocate adequate 
time for such monitoring activities. The Investigator will also ensure that the monitor or other compliance or quality assurance reviewer is given access to all the above noted study -related 
documents and study related facilities (e.g. pharmacy, diagnostic laboratory, etc.), and has adequate space to conduct the monitoring visit.  
10.8    Auditing and Inspecting 
The investigator will permit study -related monitoring, audits, and inspections by the IRB, 
government regulatory bodies, and University compliance and quality assurance groups of all study related documents (e.g. source documents, regulatory documents, data collection 
Version Date: 11 -30-2021  UPCC 21520  
42 
 instruments, study data etc.). The investigator will ensure the capability for inspections of 
applicable study -related facilities (e.g. pharmacy, diagnostic laboratory, etc.). 
 
Participation as an investigator in this study implies acceptan ce of potential inspection by 
government regulatory authorities and applicable University compliance and quality assurance offices.  
 
If an audit of this or any other study is requested by any regulatory authority, the Investigator will 
inform Array of the request.  The study site will permit access to all necessary records. 
 
11.0   STATISTICAL CONSIDERATIONS  
11.1   Design 
This is a single arm phase II study of Binimetinib and Hydroxychloroquine for patients with 
advanced KRAS mutant NSCLC. This study will be conducte d in two stages using Simon’s 
Optimal Design (Controlled Clinical Trials 10:1-10, 1989). A number of innovative correlative 
studies are planned.  
11.2   Objectives  
The primary objectives are to determine: 
• objective response rate (ORR)  
• safety & tolerability  
 
The s econdary objectives are to determine: 
• progression- free survival (PFS) and overall survival (OS)  
• changes in ctDNA KRAS allelic frequency (blood)  
 
The correlative objectives are to determine: 
• association between objective response and pre -treatment tumor expression of PPT1, LC3, 
ALDH1A1 and HLTF biomarkers  
• differences in pre-treatment and Week 6 tumor expression of PPT1, LC3, ALDH1A1 and 
HLTF biomarkers  
• changes autophagic vesicles/cell in serial tumor tissue samples  
• evaluate pharmacokinetics and pharmacodynamics of HCQ, to determine whether changes 
in blood-based autophagy biomarkers reflect tissue-based changes in autophagy (See 
Section 18)  
11.3    Endpoints 
• Objective Response will be scored using RECIST. The objective response rate is defined as 
the percentage of patients who achieve a complete or partial response. Following an intent-
to-treat analysis plan, all patients who receive at least one dose of the combination regimen will be included in the analysis of response.  
• Dura tion of response: from time of first catageroization as a PR or CR to the time of 
progressive disease.  
• Safety: NCI Common toxicity criteria (CTCAE v5.0) will be employed to grade toxicities.  
Version Date: 11 -30-2021  UPCC 21520  
43 
 • Progression -free survival will be defined as days from start of treatment to first documented 
disease progression, death due to any cause or last patient contact. Patients who are alive 
and have not progressed at the time of statistical analysis will be censored on the most 
recent date that progression-free status is documented (i.e., imaging date). For patients 
treated beyond progression (in the setting of an isolated lesion) with consent of study chair, 
PFS will be time to first progression but time to second progression will be recorded 
separately.  
• Overall survival  will be defined as days from start of treatment to death due to any cause or 
last patient contact. Patients who are alive at the time of statistical analysis will be censored for survival.   
• Biomarkers: PPT1, LC3, ALDH1A1 and HLTF will be measured in pre-treatment tissue  and 
at Week 6.  
• Median number of autophagic vesicles/cell in tumor tissue 
• HCQ PK -PD (See Section 11.5) 
11.4    Simon 2-stage Design 
After treatment with standard of care chemotherapy or chemo-immunotherapy, the standard of care for the treatment of progressive NSCLC is docetaxel. The ORR to docetaxel is 14% (Garon 
et al Lancet 2014).  This experimental regimen will be considered not worthy of further 
development if the ORR is 10% (clearly inferior to docetaxel) and considered worthy of further 
development if the ORR  is 30%.  
• Stage 1: Ten patients will be entered into the first stage of the study. If 1 or fewer of these 10 patients respond, then the trial will be terminated. If at least 2 of these 10 patients respond, then proceed to Stage 2.  
• Stage 2: Nineteen additional will be entered (total of 29) into the second stage of the study. 
If 5 or fewer of the 29 patients respond, then it will be concluded that the regimen does not 
merit further investigation. If 6 or more of the 29 patients respond, then it will be concluded 
that the regimen does merit further investigation.  
 
The trial is designed with the following characteristics:  
• False positive error:  If the true response rate is 10%, then the probability of recommending 
the regimen for further investigation, is no more than 0.05. 
• Power: If the true response rate is 30%, then the probability of recommending the regimen for further investigation, is at least 0.80. 
• If the true response rate is 10%, then the probability of early termination (PET)  is 0.74 after 
10 patients have been treated. 
11.5   Plans for Data Analysis 
Primary  
• The objective response rate and 95% exact confidence interval will be calculated.  
• All observed toxicities will be graded and tabled (worse grade experienced in all cycles). The 
overall rate of >  grade 3 toxicity and 95% exact confidence interval will be calculated.  
Secondary  
• Progression -free survival and overall survival will be estimated by the method of Kaplan and 
Meier. Median values and 95% confidence intervals will be calculated.  
Version Date: 11 -30-2021  UPCC 21520  
44 
  
 
 
Exploratory  
• Association s between objective response and expression of biomarker s pre-treatment will 
be tested using nonparametric Wilcoxon rank s um test. Comparisons  of pre- and post-
treatment biomarker expression will be conducted using Wilcoxon signed ranks test for 
paired data.  
• Describe autophagic vesicles/cell in tumor tissue at various time points using descriptive 
statistics and scatter plots.   
• To evaluate HCQ pharmacokinetics and pharmacody namics  to determine whether changes 
in blood-based autophagy biomarkers (ctDNA KRAS allelic frequency) reflect tissue -based 
changes in autophagy (autophagic vesicles/cell) , the nonlinear mixed– effects modeling 
approach (NONMEM) will be used to perform a full population PK analysis. PK-PD analyses 
to be conducted by University of Sciences of Philadelphia. Analysis methods –  See Section 
18. The key variables for the population include the Cmax and half li fe. Population PK will be 
assessed and qualitatively compared to population PK findings from other HCQ studies.  No hypothesis testing will be performed for any of the vairables.  
 
11.6    Sample Size  
The total sample size ranges from 10 to 29 patients.  
 
11.7    Study Duration  
With an estimated accrual of 20 patients  per year, accrual will continue for approximately 18 
months . ORR will be estimated when all patients have been followed for at least 6 months. In 
addition, all patients will be followed for at least 12 months, to provide estimates of PFS and OS.  
 
 
  
Version Date: 11 -30-2021  UPCC 21520  
45 
 REFERENCES  
Amaravadi, R. K., Lippincott-Schwartz, J., Yin, X. M., Weiss, W. A., Takebe, N., Timmer, W., Dipaola, R. S., Lotze, M. T., and White, E. (2011). Principles and Current Strategies for Targeting Autophagy for Cancer Treatment. Clin Cancer Res  17, 654-666. 
Amaravadi, R. K., and Thompson, C. B. (2007). The roles of therapy -induced autophagy and 
necrosis in cancer treatment. Clin Cancer Res  13, 7271-7279. 
Ascierto, P. A., Minor, D., Ribas, A., Lebbe, C., O'Hagan, A., Arya, N., Guckert, M., 
Schadendorf, D., Kefford, R. F., Grob, J . J., et al. (2013). Phase II trial (BREAK -2) of the BRAF 
inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol  31, 
3205-3211. 
Carmichael, S. J., Charles, B., and Tett, S. E. (2003). Population pharmacokinetics of 
hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit  25, 671-681. 
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., 
Garbe, C., Testori, A., Maio, M., et al. (2011). Improved survival with vemurafenib in melanoma 
with BRAF V600E mutation. N Engl J Med 364, 2507-2516. 
Falchook, G. S., Lewis, K. D., Infante, J. R., Gordon, M. S., Vogelzang, N. J., DeMarini, D. J., Sun, P., Moy, C., Szabo, S. A., Roadcap, L. T., et al. (2012a). Activity of the oral MEK inhibitor 
trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. The lancet 
oncology  13, 782-789. 
Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., Hamid, O., 
Infante, J. R., Millward, M., Pavlick, A. C. , et al. (2012b). Dabrafenib in patients with melanoma, 
untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 
379, 1893-1901. 
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., H amid, O., 
Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012a). Combined BRAF and MEK inhibition in 
melanoma with BRAF V600 mutations. N Engl J Med 367, 1694-1703. 
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. 
J., Lee, R. J., Grippo, J. F., Nolop, K., and Chapman, P. B. (2010). Inhibition of mutated, 
activated BRAF in metastatic melanoma. N Engl J Med 363, 809-819. 
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., 
Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012b). Improved survival with MEK inhibition in 
BRAF -mutated melanoma. N Engl J Med 367, 107-114. 
Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., 
Blank, C. U ., Miller, W. H., Jr., Kaempgen, E., et al. (2012). Dabrafenib in BRAF-mutated 
metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 
380, 358-365. 
Jakob, J. A., Bassett, R. L., Jr., Ng, C. S., Curry, J. L., Joseph, R. W., Alvarado, G. C., Rohlfs, 
M. L., Richard, J., Gershenwald, J. E., Kim, K. B., et al. (2011). NRAS mutation status is an 
independent prognostic factor in metastatic melanoma. Cancer. 
Kim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sos man, J. A., Fecher, L. A., 
Millward, M., McArthur, G. A., Hwu, P., et al. (2013). Phase II study of the MEK1/MEK2 inhibitor 
Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated 
with or without a BRAF inhibitor. J Clin Oncol  31, 482-489. 
Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., et al. (2012). Dabrafenib in patients with 
Val600Glu or Val600Lys BRAF- mutant melanoma metastatic  to the brain (BREAK -MB): a 
multicentre, open-label, phase 2 trial. The lancet oncology  13, 1087-1095. 
Version Date: 11 -30-2021  UPCC 21520  
46 
 Ma, X. H., Piao, S. F., Dey, S., McAfee, Q., Karakousis, G., Villanueva, J., Hart, L. S., Levi, S., 
Hu, J., Zhang, G., et al. (2014). Targeting ER stress -induced autophagy overcomes BRAF 
inhibitor resistance in melanoma. J Clin Invest. 
Marmor, M. F., Kellner, U., Lai, T. Y., Lyons, J. S., and Mieler, W. F. (2011). Revised 
recommendations on screening for chloroquine and hydroxychloroquine retinopathy. 
Ophthalmology  118, 415-422. 
Menzies, A. M., Haydu, L. E., Visintin, L., Carlino, M. S., Howle, J. R., Thompson, J. F., Kefford, 
R. F., Scolyer, R. A., and Long, G. V. (2012). Distinguishing Clinicopathologic Features of 
Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clin Cancer Res. 
Miller, C. J., Cheung, M., Sharma, A., Clarke, L., Helm, K., Mauger, D., and Robertson, G. P. 
(2004). Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF 
mutation frequencies in melanocytic neoplasms. J Invest Dermatol  123, 990-992. 
Mocellin, S., Hoon, D., Ambrosi, A., Nitti, D., and Rossi, C. R. (2006). The prognostic value of 
circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin 
Cancer Res  12, 4605-4613. 
Panka, D. J., Mier, J. W., and Sullivan, R. J. (2014). Assaying for BRAF V600E in tissue and blood in melanoma. Methods Mol Biol  1102, 117 -136. 
Poole, B., and Ohkuma, S. (1981). Effect of weak bases on the intralysosomal pH in mouse peritoneal  macrophages. J Cell Biol  90, 665-669. 
Projean, D., Baune, B., Farinotti, R., Flinois, J. P., Beaune, P., Taburet, A. M., and Ducharme, J. 
(2003). In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as 
the main isoforms catalyz ing N -desethylchloroquine formation. Drug Metab Dispos  31, 748-754. 
Ribas, A., and Flaherty, K. T. (2011). BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol  8, 426-433. 
Somer, M., Kallio, J., Pesonen, U., Pyykko, K., Huupponen, R., and Scheinin, M. (2000). 
Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol  49, 
549-554. 
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, 
G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012). Survival in BRAF V600-
mutant advanced melanoma treated with vemurafenib. N Engl J Med 366, 707-714. 
Sotelo, J., Briceno, E., and Lopez -Gonzalez, M. A. (2006). Adding chloroquine to conventional 
treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann 
Intern Med 144, 337-343. 
  
Version Date: 11 -30-2021  UPCC 21520  
47 
 APPENDIX A: ECOG PERFORMANCE ST ATUS  
 
 
ECOG PERFORMANCE STATUS*  
Grade  ECOG  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g., light house work, office work  
2 Ambulatory and capable of all self -care but unable to carry out any work 
activities. Up and about more than 50% of waking hours  
3 Capable of only limited self -care, confined to bed or chair more than 50% of 
waking hours  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or 
chair  
5 Dead  
* As publis hed in Am. J. Clin. Oncol.:  
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity 
And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649- 655, 1982.   
The ECOG Performance Status is in the public domain therefore available for public use. To duplicate the 
scale, please cite the reference above and credit the Eastern Cooperative Oncology Group, Robert Comis M.D., Group Chair.  
 
                        
              
Version Date: 11 -30-2021  UPCC 21520  
48 
  
APPENDIX B:  DEFINITION OF NON -CHILDBEARING POTENT IAL AND MEDICALLY 
ACCEPTABLE METHODS O F BIRTH CONTROL  
 Non-childbearing potential is defined as any of the following (by other than medical reasons):  
 
1. ≥45 years of age and has not had menses for  >2 years  
 
2. Amenorrhoeic for <2 years without a hysterectomy and oophorectomy and a follicle-
stimulating hormone value in the postmenopausal range upon pre-study (screening) 
evaluation 
 
3. Post hysterectomy, oophorectomy or tubal ligation 
 
Females: Women of childbearing potential must have a negative serum pregnancy test within 7 days of 
the first dose of study therapy and agree to use a highly effective contraception method during 
the treatment period and for at least 3 months  following the last dos e of study therapy  
 
Males: 
Men with partners of child-bearing potential must agree along with their partner to use a highly 
effective contraception method during the treatment period and for at least 3 months following the last dose of study therapy  
 Accep table methods include: 
• Condoms  
• Diaphragm  
• Cervical cap 
• Intra-uterine device 
• Surgical sterilization (tubal ligation or vasectomy)  
• Oral contraceptives  
 If condoms are used as a barrier method, a spermicidal agent should be added as a double barrie r protection.  
 Cases of pregnancy that occur during maternal exposures to study therapy should be reported. 
If a patient is determined to be pregnant following study therapy initiation, she must discontinue 
treatment immediately. Data on fetal outcome and breast-feeding are to be collected for 
regulatory reporting and drug safety evaluation.  
Abstinence at certain times of the cycle, such as during ovulation or after ovulation, or 
withdrawal are not acceptable methods.  The list of methods above is not exhaustive and 
additional contraception methods may also be acceptable if approved by the study doctor.  
 